<SEC-DOCUMENT>0001213900-24-037258.txt : 20240429
<SEC-HEADER>0001213900-24-037258.hdr.sgml : 20240429
<ACCEPTANCE-DATETIME>20240429170017
ACCESSION NUMBER:		0001213900-24-037258
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240429
DATE AS OF CHANGE:		20240429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		24892272

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>ea0204829-10ka1_therapeu.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 29 18:38:14 UTC 2024 -->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:txmd="http://www.therapeuticsmd.com/20231231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>UNITED
STATES </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Washington,
D.C. 20549 </b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-5521">10-K/A</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Amendment
No. 1) </b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-5522">&#9746;</ix:nonNumeric>
<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-5523"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-5524">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-5525">2023</ix:nonNumeric></ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>or</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-5526">&#9744;</ix:nonNumeric>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
the transition period from _______ to</b> _______</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Commission
File Number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-5527">001-00100</ix:nonNumeric>&#160;</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_001.jpg"/></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-5528">THERAPEUTICSMD,
INC.</ix:nonNumeric>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Exact
name of Registrant as specified in its Charter) </b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 49%"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-142"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 49%"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-148"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>87-0233535</b></span></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State or other jurisdiction of<br/> incorporation or organization)</b></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S. Employer Identification No.)</b></span></td></tr> </table><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-5529">951 Yamato Road</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-5530">Suite 220</ix:nonNumeric></b></span></td> <td style="vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="vertical-align: top; width: 49%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-5531">Boca Raton</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-5532">Florida</ix:nonNumeric></b></span></td> <td style="padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-181"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>33431</b></span></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address of principal executive offices)</b></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip Code)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-5533">561</ix:nonNumeric>-<ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-5534">961-1900</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Registrant&#8217;s
telephone number, including area code) </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(b) of the Act: </b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of Each Class</b></span></td> <td style="text-align: center; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading symbol</b></span></td> <td style="text-align: center; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-232"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock, par value $0.001 per share</b></span></ix:nonNumeric></td> <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-238"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TXMD</b></span></ix:nonNumeric></td> <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-5535">Nasdaq</ix:nonNumeric> Stock Market LLC</b></span></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(g) of the Act: None</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-5536">No</ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-5537">No</ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-5538">Yes</ix:nonNumeric> &#9746; No &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation&#160;S-T&#160;(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-5539">Yes</ix:nonNumeric> &#9746; No &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a&#160;non-accelerated&#160;filer, a smaller
reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large Accelerated Filer</span></td> <td style="width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-5540">Non-accelerated filer</ix:nonNumeric>&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-305"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-311"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:IcfrAuditorAttestationFlag" id="ixv-5541">&#9746;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If securities
are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included
in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-5542">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant&#160;to &#167;240.10D-1(b).
&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2&#160;of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-5543">&#9746;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">As of June
30, 2023, the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the voting and&#160;non-voting&#160;common
equity held by&#160;non-affiliates&#160;computed by reference to the market price at which the common equity was last sold was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd" id="ixv-5544">34,439,072</ix:nonFraction>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of April 19, 2024, there were outstanding <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-5545">11,532,443</ix:nonFraction> shares of the
registrant&#8217;s common stock, par value $0.001 per share.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif"><b>Auditor Name:</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif"><b>Auditor Location:</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif"><b>Auditor Firm ID:</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Berkowitz Pollack Brant, Advisors + CPAs</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">West Palm Beach, FL</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">52</span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-392"><span style="font-family: Times New Roman, Times, Serif">GRANT THORNTON LLP</span></ix:nonNumeric></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-397"><span style="font-family: Times New Roman, Times, Serif">Miami, Florida</span></ix:nonNumeric></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-402"><span style="font-family: Times New Roman, Times, Serif">248</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>EXPLANATORY
NOTE </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AmendmentDescription-c0_cont_1" name="dei:AmendmentDescription" id="ixv-437"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif">This
Amendment No. 1 on Form 10-K/A, or the Form 10-K/A, is being filed by TherapeuticsMD, Inc., or the Company, in order to disclose information
required by Items 10, 11, 12, 13 and 14 of Part III of Form 10-K, which information was omitted from the Company&#8217;s Form 10-K for
the fiscal year ended December 31, 2023 (the &#8220;Original Form 10-K&#8221;), in reliance on Instruction G to Form 10-K. The Original
Form 10-K was filed with the Securities and Exchange Commission, or SEC, on March 29, 2024. </span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_AmendmentDescription-c0_cont_2" id="_AmendmentDescription-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif">The
Company does not expect to file its definitive proxy statement for its upcoming annual stockholders&#8217; meeting within 120 days of
the end of its most recent fiscal year (as required under Instruction G to Form 10-K). Therefore, the Company is filing this Form 10-K/A
in order to include information that would have been contained in the definitive proxy statement into the Original Form 10-K. The Company
is also filing as exhibits to this Form 10-K/A new certifications with respect to this filing by its principal executive officer and
principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002; accordingly, Item 15 of Part IV has also been
amended to reflect the filing of these new exhibits. Because no financial statements are being filed in this Form 10-K/A, and this Form
10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications
have been omitted. The Company is also not filing new certifications required under Section 906 of the Sarbanes-Oxley Act of 2002, since
no financial statements are being filed with this Form 10-K/A. Finally, the Company is filing this Form 10-K/A to delete the reference
on the cover of the Original Form 10-K to the incorporation by reference of portions of its definitive proxy statement into Part III
of the Original Form 10-K.&#160;</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_AmendmentDescription-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif">This
Form 10-K/A is limited in scope to the items identified above and should be read in conjunction with the Original Form 10-K and the Company&#8217;s
other filings with the SEC. This Form 10-K/A does not reflect events occurring after the filing of the Original Form 10-K or modify or
update those disclosures affected by subsequent events. Consequently, all other information is unchanged and reflects the disclosures
made at the time of the filing of the Original Form 10-K.&#160;</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>










</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Part III
    </span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 82%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Directors, Executive Officers and
    Corporate Governance</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Executive Compensation</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Security Ownership of Certain Beneficial
    Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Certain Relationships and Related
    Transactions, and Director Independence</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Principal Accountant Fees and Services</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Part IV
    </span></b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Signatures</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
III </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item
10. Directors, Executive Officers and Corporate Governance </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Directors
</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following
table sets forth certain information regarding the current directors of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tommy G. Thompson</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board <sup>(2)</sup></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cooper C. Collins</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    <sup>(1)(2)</sup></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gail K. Naughton, Ph.D.</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    <sup>(1)</sup></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin H. Roberts</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    <sup>(1)(2)</sup></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Compensation Committee.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Audit Committee. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 18%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>TOMMY
    G. THOMPSON</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Chairman
    of the Board</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Director
    Since:</b> 2012</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Age:
    </b>81</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Committee:</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audit</span></p></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 81%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Biographical
    Information</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Tommy
    G. Thompson has served as a director of our company since May 2012 and as the Chairman of the Board of Directors since March 2024.
    He previously served as the Chairman of the Board of Directors from May 2012 until September 2022 and as Executive Chairman of the
    Board from September 2022 until March 2024. From July 2020 until March 2022, Secretary Thompson served as the Interim President of
    the University of Wisconsin system. Secretary Thompson also serves as the Chief Executive Officer of Thompson Holdings, a consulting
    firm. As the Governor of Wisconsin from January 1987 to February 2001, Secretary Thompson was perhaps best known for his efforts
    to revitalize the Wisconsin economy, for his national leadership on welfare reform, and for his work toward expanding healthcare
    access across all segments of society. As the former Secretary of the U.S. Department of Health &amp; Human Services, or HHS, from
    February 2001 to January 2005, Secretary Thompson served as the nation&#8217;s leading advocate for the health and welfare of all
    Americans. Secretary Thompson was a partner in the law firm of Akin Gump Strauss Hauer &amp; Feld LLP, or Akin Gump, from March 2005
    to January 2012, when he resigned to run for the United States Senate. Secretary Thompson served as an Independent Chairman of the
    Deloitte Center for Health Solutions, a healthcare consulting company, from March 2005 to May 2009. At the Deloitte Center for Health
    Solutions and at Akin Gump, Secretary Thompson built on his efforts at HHS to work toward developing solutions to the healthcare
    challenges facing American families, businesses, communities, states, and the nation as a whole. Secretary Thompson has also served
    as the President of Logistics Health, Inc., a provider of medical readiness and homeland security solutions, from February 2005 to
    January 2011. Secretary Thompson has served as a Senior Fellow for the Bipartisan Policy Center, a non-profit organization focused
    on bipartisan advocacy and policymaking, since July 2013. Secretary Thompson also serves as a member of the board of directors for
    United Therapeutics Corporation [NASDAQ: UTHR] and Healthpeak Properties, Inc. (f/k/a Physicians Realty Trust) [NYSE: DOC]. Secretary
    Thompson also served as a member of the boards of directors of Tyme Technologies, Inc. [NASDAQ: TYMI] from August 2017 to February
    2020, Centene Corporation [NYSE: CNC] from April 2005 to January 2022 and Scilex Holding Company [NASDAQ: SCLX] from 2022 to 2023,
    and has historically served on the boards of directors of other public companies.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Key
    Qualifications and Experience</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We believe
    Secretary Thompson&#8217;s experience in public service and on the boards of directors of numerous public companies, particularly
    his services and knowledge related to the healthcare industry as a whole, makes him well suited to serve on our Board of Directors.
    Secretary Thompson received both his B.S. and J.D. from the University of Wisconsin-Madison.</span></p></td></tr>

<tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>COOPER
    C. COLLINS</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Director
    Since:</b> 2012</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Age:
    </b>44</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Committees:</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audit</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Compensation</span></p></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Biographical
    Information</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Cooper
    C. Collins has served as a director of our company since February 2012. Mr. Collins has served as Chief Executive Officer of Fortis
    BioPharma LLC since June 2015. Mr. Collins served as Chief Strategy Officer of Pernix Therapeutics Holdings, Inc. [NASDAQ: PTX],
    or Pernix, from May 2013 until April 2014, as its President and Chief Executive Officer from March 2010 until May 2013, and as a
    director from March 2010 until February 2014. Mr. Collins joined Pernix Therapeutics, Inc., a predecessor of Pernix, in 2002, where
    he was appointed as a director in January 2007, its President in December 2007 and its Chief Executive Officer in June 2008, serving
    in those three capacities until March 2010. From December 2005 to December 2007, Mr. Collins served as Vice President of Business
    and Product Development of Pernix Therapeutics, Inc. and as its Territory Manager from December 2003 to December 2005. Mr. Collins
    was employed for three years by the National Football League franchise, the New Orleans Saints, in its media relations department.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Key
    Qualifications and Experience</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We believe
    Mr. Collins&#8217; specialty pharmaceutical company knowledge and executive experience provide the requisite qualifications, skills,
    perspectives, and experience that make him well qualified to serve on our Board of Directors. While on a football scholarship, Mr.
    Collins received a B.A. from Nicholls State University, where he later received an M.B.A.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>







</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 18%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>GAIL
    K. NAUGHTON,<br/>
    PH.D. </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Director
    Since:</b> 2020</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Age:
    </b>68</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Committee:</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Compensation</span></p></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 81%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Biographical
    Information</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Gail
    K. Naughton, Ph.D. has served as a director of our company since March 2020. Dr. Naughton has served as the Chief Scientific Officer
    and Chief Business Development Officer of Histogen, a company she founded which is focused on the development of novel solutions
    based on the products of cells grown under simulated embryonic conditions, since April 2017. Dr. Naughton served as the Chairman
    and Chief Executive Officer of Histogen from June 2007 until April 2017. Prior to Histogen, Dr. Naughton was the Vice Chairman of
    Advanced Tissue Sciences, Inc., a human-based tissue engineering company, from March 2002 to October 2002, President from August
    2000 to March 2002, President and Chief Operating Officer from 1995 to 2000 and Executive Vice President, Chief Operating Officer
    from 1991 to 1995. Dr. Naughton also served as Dean of the College of Business Administration at San Diego State University from
    August 2002 to June 2011. She has spent over 30 years extensively researching the tissue engineering process, holds over 105 U.S.
    and foreign patents, and has founded two regenerative medicine companies. Dr. Naughton has brought several tissue engineered products
    to market including a product for severe burns (TransCyte), a dermal replacement for diabetic ulcers (Dermagraft), an aesthetic dermal
    filler (Cosmederm/Cosmeplast), and SkinMedica&#8217;s TNS product for skin care. Dr. Naughton has been extensively published and
    a frequent speaker in the field of tissue engineering. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year
    award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering. Dr. Naughton
    also serves as a member of the board of directors for CEL-SCI Corporation [NYSE American: CVM] and previously served as a member
    of several public company boards of directors since 1988, including Cytori Therapeutics, Inc. [NASDAQ: CYTX] from July 2014 until
    January 2018.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Key
    Qualifications and Experience</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We believe
    Dr. Naughton&#8217;s extensive executive experience, her in-depth knowledge of the healthcare industry and regenerative medicine
    technology, her experience developing FDA-approved products, and her service on other public company boards and committees, provide
    the requisite qualifications, skills, perspectives, and experience that make her well qualified to serve on our Board of Directors.
    Dr. Naughton received her B.S. in Biology from St. Francis College, her M.S. in Histology and her Ph.D. in Hematology from the New
    York University Medical Center and her E.M.B.A. from UCLA.</span></p></td></tr>

<tr>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>JUSTIN
    ROBERTS</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Director
    Since:</b> 2022</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Age:
    </b>41</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Committees:</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Audit</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Compensation</span></p></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Biographical
    Information</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Mr. Roberts
    is a Partner at Rubric Capital Management LP, a role he has held since the formation of the company in 2016. He currently serves
    as a Non-Executive Director of Mereo BioPharma [NASDAQ: MREO]. Before Rubric he spent seven years at Point72 Asset Management. Mr.
    Roberts has also held roles at ZS Associates, Moore Capital Management, and began his career at Lehman Brothers as an investment
    banker in their M&amp;A practice.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Key
    Qualifications and Experience</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We believe
    Mr. Roberts&#8217; extensive executive experience, his finance background, and his service on other public company boards and committees,
    provide the requisite qualifications, skills, perspectives, and experience that make him well qualified to serve on our Board of
    Directors. Mr. Roberts graduated with honors from Johns Hopkins University.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Executive
Officers </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following
table sets forth certain information regarding our current executive officers:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marlan D. Walker</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Ziegler</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Financial and Accounting Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Listed below
are biographical descriptions of our current executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Marlan
Walker</i> has served as Chief Executive Officer of our company since December 2022. Previously he served as General Counsel of our company
from March 2016. Mr. Walker previously also served as Chief Development Officer from April 2018 to December 2019 and as our Corporate
and Intellectual Property Counsel from June 2013 until he became our General Counsel. Mr. Walker&#8217;s experience is focused in management
of legal issues and risk in the life science industries across a variety of disciplines. His legal practice prior to his time at TherapeuticsMD
included long-term portfolio strategy and management, patent preparation and prosecution, contract negotiation and drafting, life-cycle
management, and Hatch-Waxman matters. After law school, he took a position at Greenberg Traurig, LLP in August 2005. In March of 2009,
he moved to Luce Forward Hamilton &amp; Scripps. Mr. Walker accepted an in-house position as Intellectual Property Counsel for Medicis
Pharmaceutical Corp. in June 2011, which was acquired by Valeant Pharmaceutical International, Inc. in December 2012. In February 2013,
Mr. Walker accepted a position at Kilpatrick Townsend &amp; Stockton, but chose to move in-house again in June 2013, when he accepted
a position at our company. Mr. Walker graduated from Arizona State University Sandra Day O&#8217;Connor College of Law with his J.D.
in 2004, and an LL.M. in Intellectual Property Law at The George Washington University Law School in 2005. He holds a Master&#8217;s
Degree in Molecular Biology and a B.S. degree, both earned from Brigham Young University<i>.</i>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Joseph Ziegler</i> has served as Principal Financial and Accounting
Officer of our company since August 2023 and has served as founder and chief executive officer of JZ Advisory Group, a consulting company
largely focused on providing fractional CFO and outsourced accounting services to middle-market and entrepreneurial businesses, since
January 2022. He previously served as the Chief Financial Officer of DAS Health, a private equity owned provider of IT Services to healthcare
providers, from April 2021 to December 2021 and as the Chief Financial Officer of Encompass Onsite, a provider of end-to-end property
solutions, from November 2018 to February 2021. Prior to joining Encompass, he held multiple roles as a CFO in the healthcare industry,
including private equity backed specialty pharmacy Biomatrix and Novis Pharmaceuticals. Mr. Ziegler has been a director of Progressive
Care Inc. since December 2021. He earned his B.S. in Finance and an M.B.A. from Florida Atlantic University.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>CORPORATE
GOVERNANCE </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Director
Independence </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Since October
9, 2017, our common stock has been listed on the Nasdaq Global Select Market of the Nasdaq Stock Market LLC, or Nasdaq, under the symbol
&#8220;TXMD.&#8221; From April 23, 2013 to October 6, 2017, our common stock was listed on the NYSE American under the symbol &#8220;TXMD.&#8221;
Under the rules of Nasdaq, independent directors must comprise a majority of a listed company&#8217;s board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Our Board
of Directors has affirmatively determined, after considering all the relevant facts and circumstances, that each of Dr. Gail Naughton,
and Messrs. Tommy G. Thompson, Cooper C. Collins and Justin Roberts is an independent director, as &#8220;independence&#8221; is defined
under the applicable rules and regulations of the SEC and the listing standards of Nasdaq, and does not have a relationship with us (either
directly or as a partner, stockholder, or officer of an organization that has a relationship with us) that would interfere with their
exercise of independent judgment in carrying out their responsibilities as directors. Accordingly, a majority of our directors are independent,
as required under the applicable Nasdaq rules. There are no family relationships among any of our directors or officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Committee
Charters, Corporate Governance, and Code of Ethics </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Our Board
of Directors has adopted charters for the Audit and Compensation Committees describing the authority and responsibilities delegated to
each committee by our Board of Directors. Our Board of Directors has also adopted Corporate Governance Guidelines, a Code of Conduct
and Ethics, and a Code of Ethics for the Chief Executive Officer and senior financial officers of our company. We post on our website,
at <i>www.therapeuticsmd.com</i>, the charters of our Audit and Compensation Committees; our Corporate Governance Guidelines, Code of
Conduct and Ethics, and Code of Ethics for the Chief Executive Officer and senior financial officers, and any amendments or waivers thereto;
and any other corporate governance materials contemplated by the SEC or Nasdaq. These documents are also available in print to any stockholder
requesting a copy in writing from our corporate secretary at our executive offices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Executive
Sessions </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We regularly
schedule executive sessions in which non-employee directors will meet without the presence or participation of management, with at least
one of such sessions including only independent directors. Mr. Thompson, as the Chairman of our Board of Directors, chairs the executive
sessions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Board
Committees </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Our Board
of Directors has an Audit Committee and a Compensation Committee, each consisting entirely of independent directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Given the
relatively small size of our Board of Directors and the desire to involve the entire Board of Directors in nominating decisions, we have
elected to no longer have a separate Nominating Committee. Since we do not have a Nominating Committee, our independent directors, who
currently constitute all of the Board of Directors, determine the director nominees. Our Board of Directors may employ a variety of methods
for identifying and evaluating director nominees. If vacancies are anticipated or arise, our Board of Directors considers various potential
candidates who may come to our attention through current Board members, professional search firms, stockholders or other persons. These
candidates may be evaluated by our Board of Directors at any time during the year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 8 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In evaluating
a director candidate, our Board of Directors will review their qualifications including capability, availability to serve, conflicts
of interest, general understanding of business, understanding of our business and technology, educational and professional background,
personal accomplishments and other relevant factors. Our Board of Directors has not established any specific qualification standards
for director nominees, and we do not have a formal diversity policy relating to the identification and evaluation of nominees for director,
although from time to time the Board of Directors may identify certain skills or attributes as being particularly desirable to help meet
specific needs that have arisen. Our Board of Directors may also interview prospective nominees in person or by telephone. After completing
this evaluation, the Board of Directors will determine the nominees. The Board has not adopted a formal process for considering director
candidates who may be recommended by stockholders. However, our policy is to give due consideration to any and all such candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit Committee</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 10%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Members</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Cooper
    C. Collins, Chair</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Justin
    Roberts</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Tommy
    G. Thompson</span></p></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 89%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The purpose
    of the Audit Committee is to oversee our financial and reporting processes and the audits of our financial statements and to provide
    assistance to our Board of Directors with respect to its oversight of the integrity of our financial statements, our company&#8217;s
    compliance with legal and regulatory matters, the independent registered public accountant&#8217;s qualifications and independence,
    and the performance of our independent registered public accountant. The primary responsibilities of the Audit Committee are set
    forth in its charter and include various matters with respect to the oversight of our accounting and financial reporting process
    and audits of our financial statements on behalf of our Board of Directors. The Audit Committee also selects the independent registered
    public accountant to conduct the annual audit of our financial statements; reviews the proposed scope of such audit; reviews accounting
    and financial controls with the independent registered public accountant and our financial accounting staff; and reviews and approves
    any transactions between us and our directors, officers, and their affiliates.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Audit
    Committee currently consists of Messrs. Collins, Thompson and Roberts, each an independent director of our company under the listing
    standards of Nasdaq as well as under applicable rules and regulations of the SEC, with Mr. Collins serving as Chair. Our Board of
    Directors has determined that Mr. Thompson (whose background is detailed above) qualifies as an &#8220;audit committee financial
    expert&#8221; in accordance with applicable rules and regulations of the SEC.</span></p></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation Committee</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Members</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Gail
    Naughton, Chair</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Cooper
    C. Collins</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Justin
    Roberts</span></p></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The purpose of the Compensation
    Committee includes, among other things, determining, or recommending to our Board of Directors for determination, the compensation
    of our Chief Executive Officer and other executive officers and directors, and discharging the responsibilities of our Board of Directors
    relating to our compensation programs. Pursuant to its charter, the Compensation Committee may delegate any of its responsibilities
    to a subcommittee comprised of one or more members of the Compensation Committee. The Compensation Committee currently consists of
    Dr. Naughton and Messrs. Collins and Roberts, each an independent director of our company under the listing standards of Nasdaq as
    well as under applicable rules and regulations of the SEC, with Dr. Naughton serving as Chair.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 9 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Board&#8217;s
Role in Risk Oversight </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Risk is inherent
in every business. As is the case in virtually all businesses, we face a number of risks, including operational, economic, financial,
legal, regulatory, and competitive risks. Our management is responsible for the day-to-day management of the risks we face. Our Board
of Directors, as a whole and through its committees, has responsibility for the oversight of risk management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Our Board
of Directors&#8217; involvement in our business strategy and strategic plans plays a key role in its oversight of risk management, its
assessment of management&#8217;s risk appetite, and its determination of the appropriate level of enterprise risk. Our Board of Directors
receives updates at least quarterly from senior management and periodically from outside advisors regarding the various risks we face,
including operational, cybersecurity and information technology, economic, financial, legal, regulatory, and competitive risks. Our Board
of Directors also reviews the various risks we identify in our filings with the SEC as well as risks relating to various specific developments,
such as debt and equity issuances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The committees
of our Board of Directors assist our Board of Directors in fulfilling its oversight role in certain areas of risks. The Audit Committee
oversees the financial and reporting processes of our company and the audit of the financial statements of our company and provides assistance
to our Board of Directors with respect to the oversight and integrity of the financial statements of our company, our company&#8217;s
compliance with legal and regulatory matters, the independent auditor&#8217;s qualification and independence, and the performance of
our independent auditor. The Audit Committee also receives reports regarding our compliance program and our cybersecurity and information
technology programs. The Compensation Committee considers the risks that our compensation policies and practices may have in attracting,
retaining, and motivating valued employees and endeavors to assure that it is not reasonably likely that our compensation plans and policies
would create undue risk or have a material adverse effect on our company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Board
Diversity </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We seek diversity
in experience, viewpoint, education, skill, and other individual qualities and attributes to be represented on our Board of Directors.
We believe directors should have various qualifications, including individual character and integrity; business experience and leadership
ability; strategic planning skills, ability, and experience; requisite knowledge of our industry and finance, accounting, and legal matters;
communications and interpersonal skills; and the ability and willingness to devote time to our company. We also believe the skill sets,
backgrounds, and qualifications of our directors, taken as a whole, should provide a significant mix of diversity in personal and professional
experience, background, viewpoints, perspectives, knowledge, and abilities. Nominees are not to be discriminated against on the basis
of race, religion, national origin, sex, sexual orientation, disability, or any other basis prohibited by law. The assessment of directors
is made in the context of the perceived needs of our Board of Directors from time to time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">All of our
directors have held high-level positions in business or professional service firms and have experience in dealing with complex issues.
We believe that all of our directors are individuals of high character and integrity, are able to work well with others, and have committed
to devote sufficient time to the business and affairs of our company. In addition to these attributes, the description of each director&#8217;s
background sets forth above indicates the specific experience, qualifications, and skills necessary to conclude that each individual
should continue to serve as a director of our company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 10 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Board
Diversity Matrix set forth below reports self-identified diversity statistics for our Board of Directors in the format required by Nasdaq&#8217;s
rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Diversity
    Matrix for TherapeuticsMD, Inc. (As of April 19, 2024)</b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board size: </b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total number of directors</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gender:</b></span></td>
    <td style="width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Female</span></td>
    <td style="width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Male</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Directors who identify in
    any of the categories below:</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">African American or Black</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alaskan Native or Native American</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asian</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hispanic or Latinx</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Native Hawaiian or Pacific Islander</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">White</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two or More Races or Ethnicities</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LGBTQ+</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did Not Disclose Demographic Background</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Board
Leadership Structure </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We believe
that effective board leadership structure depends on the experience, skills, and personal interaction among persons in leadership roles
as well as the needs of our company at any point in time. We currently maintain separate roles between the Chief Executive Officer and
the Chairman of the Board of Directors in recognition of the differences between the two responsibilities. Our Chief Executive Officer
is responsible for setting our strategic direction and day-to-day leadership and performance of our company. The Chairman of the Board
of Directors provides input to the Chief Executive Officer, sets the agenda for board meetings, and presides over meetings of the full
Board of Directors as well as executive sessions of our Board of Directors. Our Board of Directors believes that our current leadership
structure provides the most effective leadership model for our company, as it promotes balance between the Board of Directors&#8217;
independent authority to oversee our business and the Chief Executive Officer and his management team, which manage the business on a
day-to-day basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 11 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Compensation
Recovery Policy </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In 2023,
we adopted a policy on recoupment of incentive compensation, or clawback policy, which provides for recoupment of compensation in certain
circumstances in the event of a restatement of our financial results, in accordance with the requirements of SEC rules and Nasdaq listing
standards implementing the requirement of Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the &#8220;Dodd-Frank
Act&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Anti-Hedging
and Anti-Pledging Policy </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In April
2020, the Board of Directors amended the Company&#8217;s Code of Conduct and Ethics to include a policy regarding hedging and pledging
transactions. Pursuant to the policy, directors, officers, and employees are prohibited from: (1) directly or indirectly engaging in
any hedging transactions with respect to any directly or indirectly owned securities of the company, which includes the purchase of any
financial instrument (including puts, calls, equity swaps, forward contracts, collars, exchange funds or other derivative securities)
on an exchange or in any other market in order to hedge or offset any decrease in the market value of such securities; (2) engaging in
short sale transactions or forward sale transactions or any short-term or speculative transactions in the company&#8217;s securities
or in other transactions in the company&#8217;s securities that may lead to inadvertent violations of insider trading laws; and (3) pledging
securities of the company as collateral for a loan or otherwise using securities of the company to secure a debt, including through the
use of traditional margin accounts with a broker.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Board
and Committee Meetings </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors held a total of 23 meetings during the fiscal
year ended December 31, 2023. No director attended fewer than 75% of the aggregate of (i) the total number of meetings of our Board of
Directors and (ii) the total number of meetings held by all committees of our Board of Directors on which such director was a member.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">During the
fiscal year ended December 31, 2023, the Audit Committee held 4 meetings and the Compensation Committee held 1 meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Annual
Meeting Attendance </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We encourage
our directors to attend each annual meeting of stockholders. All of our directors virtually attended the 2023 annual meeting of stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Communications
with Directors </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Stockholders
may communicate with our Board of Directors or specific members of our Board of Directors, including our independent directors and the
members of our various board committees, by submitting a letter addressed to our Board of Directors of TherapeuticsMD, Inc. at the address
set forth in this annual report c/o any specified individual director or directors. Any such letters are forwarded to the indicated directors.
In addition, at the request of the Board of Directors, communications that do not directly relate to our Board of Directors&#8217; duties
and responsibilities as directors will be excluded from distribution. Such excluded items include, among others, &#8220;spam,&#8221;
advertisements, mass mailings, form letters, and email campaigns that involve unduly large numbers of similar communications; solicitations
for goods, services, employment or contributions; and surveys. Additionally, communications that appear to be unduly hostile, intimidating,
threatening, illegal or similarly inappropriate will also be screened for omission. Any excluded communication will be made available
to any director upon his or her request.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 12 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item
11. Executive Compensation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">As a smaller
reporting company, the rules of the U.S. Securities and Exchange Commission permit us to omit the Compensation Discussion and Analysis
section and to report the compensation of our principal executive officer, each of our two other most highly compensated executive officers
who were serving at the end of our last completed fiscal year, and up to two additional former executive officers for whom disclosure
would have been provided but for the fact that the individual was not serving as an executive officer at the end of our last completed
fiscal year (collectively, our NEOs).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">For 2023,
our NEOs were:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marlan
                                            Walker, CEO</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
                                            Ziegler, Principal Financial and Accounting Officer</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
                                            Donegan, Former Principal Financial and Accounting Officer</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In connection
with the Company&#8217;s transformation into a pharmaceutical royalty company, the termination of our executive management team (except
for Mr. Marlan Walker, our former General Counsel and current Chief Executive Officer) and all other employees was completed by December
31, 2022. Subsequent to these departures, Mr. Donegan, the former interim chief financial officer of the Company, continued to serve
as the Company&#8217;s Principal Financial and Accounting Officer pursuant to a consulting agreement until such time as Mr. Donegan transitioned
his role to a third party provider. On August 17, 2023, Mr. Donegan resigned as Principal Financial and Accounting Officer and Mr. Ziegler
succeeded Mr. Donegan as Principal Financial and Accounting Officer as of the date of Mr. Donegan&#8217;s resignation. As of December
31, 2023, we employed one full-time employee primarily engaged in an executive position. Severance obligations for terminated executive
officers were paid in accordance with their employment agreements and separation agreements as previously disclosed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Fiscal
Year 2023 Summary Compensation Table </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following
table lists the compensation of our NEOs for the years provided. The following information includes the dollar value of salaries, bonus
awards, the number of awards granted, non-equity incentive plan compensation, and certain other compensation, if any.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in; white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Name
    and Principal Position</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Salary<br/>
    ($)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Bonus<br/>
    ($)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Stock<br/>
    Awards<sup>(1)</sup><br/>
    ($)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Option<br/>
    Awards<br/>
    ($)</b></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Non-Equity<br/>
    Incentive Plan<br/>
    Compensation<sup>(2)</sup><br/>
    ($)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">All
    Other<br/>
    Compensation<br/>
    ($)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total
    <br/>
    ($)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 28%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Marlan
    D. Walker</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">476.462</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">176,535</span></td><td style="vertical-align: baseline; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(4)</sup></span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">358,400</span></td><td style="vertical-align: baseline; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(5)</sup></span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,420</span></td><td style="vertical-align: baseline; width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(6)</sup></span></td><td style="width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,019,817</span></td><td style="width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Chief
    Executive Officer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">424,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">207,500</span></td><td style="vertical-align: baseline; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">292,656</span></td><td style="vertical-align: baseline; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(5)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">622,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,224</span></td><td style="vertical-align: baseline; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(6)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,573,380</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Joseph
    Ziegler<sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,900</span></td><td style="vertical-align: baseline; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(7)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="vertical-align: baseline; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="vertical-align: baseline; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(10)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">82,900</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Principal
    Financial and Accounting Officer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Michael
    Donegan<sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">532,086</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">160,500</span></td><td style="vertical-align: baseline; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">296,000</span></td><td style="vertical-align: baseline; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(8)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">333,909</span></td><td style="vertical-align: baseline; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(9)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,286,663</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Former
    Principal Financial and Accounting Officer and former Interim Chief Financial Officer</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">307,308</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">90,000</span></td><td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">135,072</span></td><td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(8)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">363,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,860</span></td><td style="vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(9)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif">914,240</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the grant date fair value of restricted
    stock units (RSUs) and performance restricted stock units (PSUs) granted. The number of PSUs represents the maximum number of PSUs
    that may vest. The actual number of PSUs that will vest will depend on the Company&#8217;s achievement of certain performance goals.
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts in this column represent the amounts earned
    and payable under our annual performance-targeted incentive plan, which were earned and payable during the indicated fiscal year
    but portions of which may not have been paid until after the end of indicated fiscal year. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 13 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2023, we entered a master services agreement
    (the &#8220;Master Services Agreement&#8221;) with JZ Advisory Group (&#8220;JZ Advisory&#8221;), pursuant to which Joseph Ziegler
    would serve as our Principal Financial and Accounting Officer. On August 17, 2023, Mr. Donegan ceased serving as the Principal Financial
    and Accounting Officer of the Company and Mr. Ziegler began serving as Principal Financial and Accounting Officer of the Company.
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts represent retention bonuses. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For 2023, the amount represents (i) 70,000 RSUs with a grant date fair
value of $358,400. For 2022, the amount represents (i) 5,200 PSUs with a grant date fair value of $179,400 and (ii) 5,200 RSUs with a
grant date fair value of $113,256. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For 2023, other compensation paid was related to (i) employer match
to 401(k) plan of $2,000, and (ii) health and welfare benefits paid by the Company. For 2022, other compensation paid was related to (i)
employer match to 401(k) plan of $2,000, and (ii) health and welfare benefits paid by the Company.
    </span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For 2023, the amount represents the fixed fee paid
    to JZ Advisory in accordance with the Master Services Agreement. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For 2023, the amount represents 60,000 RSUs with a
    grant date fair value of $296,000. For 2022, the amount represents (i) 2,400 PSUs with a grant date fair value of $82,800 and (ii)
    4,200 RSUs with a grant date fair value of $52,272. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For 2023, other compensation paid was related to (i)
    severance of $298,077 and (ii) health and welfare benefits paid by the Company. For 2022, other compensation paid was related to
    (i) employer match to 401(k) plan of $2,000, and (ii) health and welfare benefits paid by the Company. </span></td></tr>
</table><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For 2023, the amount represents 7,500 RSUs with a grant
    date fair value of $30,000.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Outstanding
Equity Awards at Fiscal Year-End 2023</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth information with respect to outstanding equity-based awards held by our NEOs at December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Securities<br/> Underlying Unexercised&#160;Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity Award&#160;Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable<br/> (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unexercisable<br/> (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise&#160;Price<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<br/> Expiration&#160;Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-align: left">Marlan D. Walker</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/05/2014</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,900</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">201.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/05/2024</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/21/2014</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/21/2024</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/30/2019</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/30/2029</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Joseph Ziegler</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Michael Donegan</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/28/2019</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/28/2029</span></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock Awards</b></p>

</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity Incentive Plan Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity <br/> Award&#160;Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <br/> of Shares<br/> or Units<br/> of Stock<br/> That Have<br/> Not<br/> Vested<br/> (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market<br/> Value of<br/> Shares or<br/> Units of<br/> Stock <br/> That Have<br/> Not<br/> Vested<sup>(1)</sup><br/> ($)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number<br/> of Shares<br/> or Units <br/> of Stock<br/> That Have<br/> Not <br/> Vested<br/> (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market<br/> Value of<br/> Shares or<br/> Units of<br/> Stock<br/> That Have<br/> Not<br/> Vested<sup>(1)</sup><br/> ($)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-align: left">Marlan D. Walker</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">07/01/2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,155</td><td style="width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,599</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,467</td><td style="width: 1%; text-align: left"><sup>(3)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,801</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">09/29/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/23/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,466</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,799</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">03/31/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,200</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Joseph Ziegler</td><td>&#160;</td>
    <td style="text-align: center">08/17/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,500</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,875</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            amounts in this column are based on the closing price of our common stock on December 29,
                                            2023 of $2.25.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount reflects RSUs that vest one-third annually
    beginning on the equity award date. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount reflects the base number of PSUs that may
    vest. The actual number of PSUs that will vest will be between zero and two times the base number depending on the Company&#8217;s
    achievement of certain (i) revenue goals for 2023 or (ii) revenue CAGR targets from 2021 to 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount reflects the base number of PSUs that may
    vest. The actual number of PSUs that will vest will be between zero and two times the base number, depending on the total shareholder
    return milestone achieved. The performance measurement period is from April 1, 2022 to March 31, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount reflects RSUs that vest on the one year anniversary of the equity award date.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Post-Employment
Compensation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pension
Benefits </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We do not
offer any defined benefit pension plans for any of our employees. We have a 401(k) plan in which employees may participate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Other
Compensation </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Mr. Walker
is eligible to participate in our employee benefit plans, including medical and dental plans. Should we decide to hire other employees,
these plans do not discriminate in favor of executive officers and would be available to any potential employee. It is generally our
policy to not extend significant perquisites to executives that are not broadly available to our other employees. In designing these
elements, we seek to provide an overall level of benefits that is competitive with that offered by similarly situated companies in the
markets in which we operate based upon our general understanding of industry practice. These benefits are not considered in determining
the compensation of our executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 15 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Employment
Agreement </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Marlan D.
Walker has an amended and restated employment agreement, as amended (the &#8220;Walker Employment Agreement&#8221;), with the Company
that commenced on December 18, 2018, and was amended twice effective October 15, 2021 and December 30, 2022. The Walker Employment Agreement
provides that we will continue to employ Mr. Walker, and Mr. Walker will continue to serve the Company, unless sooner terminated pursuant
to the terms of the Walker Employment Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Walker Employment Agreement provides for: (i) a base salary of
$428,000 per year until April 15, 2023; thereafter, a base salary of $500,000 per year and a lump-sum bonus payment of $20,909, which
was paid in April 2023, (ii) an annual short-term incentive compensation of 50% of salary, at the discretion of our Board of Directors,
and (iii) 70,000 RSUs which vested on June 30, 2023. Mr. Walker will receive employee benefits, vacation, and other perquisites as may
be determined from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Conditions
of termination call for (i) termination immediately upon death, (ii) termination upon a disability in which Mr. Walker is unable to perform
his duties for more than six consecutive months, (iii) voluntary termination without good reason by Mr. Walker with prior notice, (iv)
involuntary termination by our Company without good cause, (v) termination for good cause, and (vi) termination for good reason wherein
Mr. Walker will have 90 days from the date of occurrence of a condition giving rise to good reason to provide a notice of termination
of his employment with the Company, which will be effective 31 days after we receive notice and the criteria remains uncorrected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Ziegler
MSA</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We entered
into the Master Services Agreement with JZ Advisory that commenced on August 15, 2023, pursuant to which, among other things, JZ Advisory
will serve as an independent consultant for the purpose of providing the Company with certain support services, including the services
of Mr. Ziegler as the Company&#8217;s Principal Financial Officer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Company
agreed to pay JZ Advisory $10,000 a month for the services provided under the Master Services Agreement during the third quarter of 2023,
which monthly rate will continue until the parties negotiate a future retainer amount. Mr.&#160;Ziegler was also granted 7,500 restricted
stock units, which vest on the earlier of one year from the date of grant or upon a change of control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Master
Services Agreement will continue through the third anniversary of the Effective Date, unless earlier terminated (the &#8220;Term&#8221;).
The Term will automatically be extended for successive one-year periods unless either party provides written notice of non-extension
no less than thirty (30)&#160;days in advance. The Master Services Agreement may be terminated pursuant to its terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Master
Services Agreement contains certain covenants and agreements of the parties, including certain indemnification obligations of each party.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Potential
Payments Upon Termination or Change in Control </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We have employment
agreements with certain of our executive officers as described above. The arrangements reflected in these employment agreements are designed
to encourage the officers&#8217; full attention and dedication to our Company currently and, in the event of any proposed change in control,
provide these officers with individual financial security. The employment agreements provide for specified payments and benefits by us
to our executive officers only upon a qualifying termination of employment as described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Termination
by Us Without Good Cause or by Executive with Good Reason - No Change in Control </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Under the
Walker Employment Agreement, for Mr. Walker, in the event of termination of the executive&#8217;s employment without &#8220;cause&#8221;
(referred to as &#8220;good cause&#8221; in the Walker Employment Agreement) or resignation by the executive for &#8220;good reason&#8221;
(as each term is defined in the Walker Employment Agreement), he would be entitled to, subject to his signing and not revoking a full
and complete release of all claims against the Company and its affiliates, (i) the sum of his salary, payable on a biweekly basis ratably
over eighteen (18) months, and one and one half times (1.5x) his target annual incentive compensation for the fiscal year in which such
termination of employment occurs, (ii) a continuation of welfare benefits for a period of two years after such termination, (iii) COBRA
benefits for a period of twenty-four (24) months following such termination, (iv) payment for any annual short-term incentive compensation
earned for the calendar year immediately preceding the calendar year of such termination, (v) unpaid accrued base salary and unused vacation
pay through the termination date, and (vi) amounts accrued but unpaid at the time of termination. Furthermore, the above obligations
of the Company are subject to the executive complying with a non-solicitation agreement of employees and customers, and a non-competition
agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 16 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Termination
or Resignation in Connection with a Change in Control </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In the event
of termination of Mr. Walker&#8217;s employment without &#8220;good cause&#8221; or resignation by the executive for &#8220;good reason&#8221;
in the 12 months following a change in control, Mr. Walker would have all the benefits and obligations for termination without a change
in control, except that he would receive the sum of his salary and continuation of welfare benefits for 18 months and would receive 150%
of his targeted annual bonus award.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Termination
by Reason of Death or Disability </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">For Mr. Walker,
in the event of termination of the executive&#8217;s employment by reason of his death or &#8220;disability&#8221; (as such term is defined
in the Walker Employment Agreement), in addition to those payments and benefits provided to salaried employees generally, including amounts
accrued but unpaid at the time of termination, he would be entitled to (i) pro-rated target annual incentive compensation for the fiscal
year in which such termination of employment occurs, payable in a lump sum, subject to the executive&#8217;s signing and not revoking
a full and complete release of all claims against the company and its affiliates in the event of a disability, (ii) immediate vesting
of all outstanding equity awards that vest solely on the passage of time, (iii) accrued but unused vacation pay through the termination
date, payable in a lump sum, and (iv) all other rights and benefits the executive is vested in, pursuant to other plans and programs
of our company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Termination
by the Executive Without Good Reason </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The table
below reflects the amount of compensation to Marlan Walker, the only NEO currently employed by the Company, assuming termination of such
executive&#8217;s employment without cause or for good reason or following a change in control of our company on December 31, 2023. Other
than as set forth below, no amounts will be paid to our NEOs in the event of termination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">Marlan
Walker </span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Executive Benefits and Payments</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Termination<br/> Without&#160;Good<br/> Cause<br/> or with Good<br/> Reason<br/> (Not in <br/> Connection<br/> with a Change<br/> in Control)<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Termination<br/> Without<br/> Good Cause<br/> or with <br/> Good Reason<br/> Following a<br/> Change in Control<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Termination&#160;by<br/> Reason of<br/> Death or<br/> Disability <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Cash severance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,233,500</td><td style="width: 1%; text-align: left"><sup>(1)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,233,500</td><td style="width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">250,000</td><td style="width: 1%; text-align: left"><sup>(3)</sup></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity awards<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,765</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,765</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,765</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of payments due to executive for (i) 18 months of his then
current salary, (ii) 150% target annual incentive compensation, (iii) health and welfare benefits for 24 months, (iv) unused PTO, and
(v) any annual short-term incentive compensation earned from the prior year that had not yet been paid by the Company. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of payments due to executive for (i) 18 months of his then
current salary, (ii) 150% target annual incentive compensation, (iii) unused PTO, and (iv) any annual short-term incentive compensation
earned from the prior year that had not yet been paid by the Company. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents full annual incentive compensation that
    would be prorated based on termination date. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Represents the value of unvested equity awards that would become fully
vested. The value is calculated by multiplying the number of shares underlying each accelerated award by the per share closing price of
the common stock on December 29, 2023.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 17 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Nonqualified
Defined Contribution and Nonqualified Deferred Compensation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We do not
offer any nonqualified defined contribution plans or nonqualified deferred compensation plans for any of our NEOs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Limitation
of Directors&#8217; Liability; Indemnification of Directors, Officers, Employees, and Agents </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Our Amended
and Restated Articles of Incorporation and bylaws, each as amended, provide that we may indemnify to the full extent of our power to
do so, all directors, officers, employees, and/or agents. The effect of this provision in the Amended and Restated Articles of Incorporation,
as amended, is to eliminate the rights of our company and our stockholders, either directly or through stockholders&#8217; derivative
suits brought on behalf of our company, to recover monetary damages from a director for breach of the fiduciary duty of care as a director
except in those instances described under Nevada law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Insofar as
indemnification by our company for liabilities arising under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
may be permitted to officers and directors of our company pursuant to the foregoing provisions or otherwise, we are aware that in the
opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>DIRECTOR
COMPENSATION </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We compensate our non-employee directors with a combination of cash
and equity. Our Board of Directors receives the following cash compensation for their service: each director receives an annual cash retainer
of $57,500; the chairperson of the Board receives an additional $22,500 annual cash retainer; the chairperson of our Audit Committee receives
an annual cash retainer of $30,000 and the other members of the Audit Committee receive an annual cash retainer of $15,000; the chairperson
of the Compensation Committee receives an annual cash retainer of $20,000 and the other members of the Compensation Committee receive
an annual cash retainer of $12,000; and the chairperson of each of our other committees receives an annual cash retainer of $12,500 and
the other members receive an annual cash retainer of $7,500. We also reimburse our directors for reasonable expenses related to attendance
at Board of Directors and committee meetings. In addition, each director received an annual award of 8,500 restricted stock units, with
the exception of Mr. Roberts. All restricted stock units granted to our directors in 2023 represent a contingent right to receive one
share of common stock and will vest on the one year anniversary of the date of grant. We do not pay our directors per meeting fees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following
table and accompanying footnotes detail compensation paid to our directors for services rendered for the year ended December 31, 2023.
Mr. Roberts is entitled to receive compensation in the same manner as our other non-employee directors, but he has elected not to receive
any compensation for his service as a non-employee director at this time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name<sup>(1)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees Earned<br/> or Paid in Cash<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock<br/> Awards<sup>(2)</sup><br/> ($)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other<br/> Compensation<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Tommy G. Thompson</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">160,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33,745</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">193,745</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Cooper C. Collins</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,245</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Gail Naughton, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,245</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Justin Roberts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, each of the directors listed
    in the &#8220;Director Compensation&#8221; table had the following awards outstanding: </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<br/> Awards<br/> (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<br/> Awards<br/> (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Tommy G. Thompson</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">42,675</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Cooper C. Collins</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Gail Naughton, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Justin Roberts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The stock awards listed above include 34,175, 5,000 and 5,000 restricted
stock units that were vested but not settled as of December 31, 2023, for each of Mr. Thompson, Mr. Collins and Dr. Naughton, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We grant RSUs for shares of common stock to non-employee
    directors. We value our RSUs by reference to our stock price on the date of grant. We recognize compensation expense for RSUs based
    on a straight-line basis over the requisite service period of the entire award. For further information, see &#8220;Note 10 - Stockholders&#8217;
    deficit&#8221; of the financial statements included in our most recent Annual Report on Form 10-K. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt">&#160;</span></span></p><div>


</div><!-- Field: Page; Sequence: 18 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>SECURITY
OWNERSHIP OF PRINCIPAL STOCKHOLDERS, DIRECTORS, AND OFFICERS </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following
table sets forth information regarding the beneficial ownership of our common stock as of April 19, 2024, by the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our directors and named executive officers;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            of our directors and executive officers as a group; and</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            person, or group of affiliated persons, who is known by us to beneficially own more than
                                            5% of our common stock.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Beneficial
ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if
he, she, or it possesses sole or shared voting or investment power of that security, including options and warrants that are currently
exercisable or exercisable within 60 days of April 19, 2024. Shares issuable pursuant to stock options, warrants, and convertible securities
are deemed outstanding for computing the percentage of the person holding such options, warrants, or convertible securities but are not
deemed outstanding for computing the percentage of any other person. Except as indicated by the footnotes below, we believe, based on
the information furnished to us, that the persons named in the table below have sole voting and investment power with respect to all
shares of common stock shown that they beneficially own, subject to community property laws where applicable. The information does not
necessarily indicate beneficial ownership for any other purpose.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Unless otherwise
indicated, the address of each beneficial owner listed in the table below is c/o TherapeuticsMD, Inc., 951 Yamato Road, Suite 220, Boca
Raton, Florida 33431.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares
    Beneficially&#160;Owned</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Name of
    Beneficial Owners</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Percent<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Executive
    Officers and Directors:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Marlan
    D. Walker<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">74,465</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Tommy
    G. Thompson<sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74,862</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cooper
    C. Collins<sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,622</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Gail
    K. Naughton, Ph.D.<sup>(5)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Justin
    Roberts</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Joseph
    Ziegler</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Michael Donegan<sup>(6)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64,253</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">All
    executives and directors as a group (6 persons)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">215,949</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">5%
    Stockholders:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Rubric
    Capital Management LP<sup>(7)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,946,908</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25.6</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents less than 1% of the outstanding shares of
    our common stock. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on 11,532,443 shares outstanding as
    of April 19, 2024. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 62,565 shares held by Mr. Walker directly
    and (ii) 11,900 shares issuable to Mr. Walker upon the exercise of vested stock options. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Includes (i) 14,312 shares held by Thompson Family Investments, LLC,
an entity solely owned by Thompson Family Holdings, LLC, an entity solely owned by Mr. Thompson, (ii) 5,954 shares held by Mr. Thompson
directly, (iii) 21 shares held indirectly by Thompson Family Holdings, LLC, (iv) 34,175 shares issuable to Mr. Thompson underlying vested
but unsettled restricted stock units and (v) 20,400 shares issuable to Mr. Thompson upon the exercise of vested stock options.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Includes (i) 46,722 shares held by Mr. Collins directly, (ii) 5,000
shares issuable to Mr. Collins underlying vested but unsettled restricted stock units and (iii) 9,900 shares issuable to Mr. Collins upon
the exercise of vested stock options.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 5,000 shares issuable to Dr. Naughton underlying vested but unsettled restricted stock units. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Includes (i) 61,853 shares held by Mr. Donegan directly and (ii) 2,400
shares issuable to Mr. Donegan upon the exercise of vested stock options. Based solely on the Form 4 filed on April 14, 2023 by Mr. Donegan.
Mr. Donegan served as the Company&#8217;s Principal Financial and Accounting Officer until his separation from employment with the Company
on August 17, 2023.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based solely on the Form 4 filed with the SEC by Rubric
    Capital Management LP on November 17, 2023. The address of Rubric Capital Management LP is 155 East 44th Street, Suite 1630, New
    York, NY 10017. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 19 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>EQUITY
COMPENSATION PLAN INFORMATION </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">As of December
31, 2023, the following table shows the number of securities to be issued upon exercise of outstanding options under equity compensation
plans approved by our stockholders, which plans do not provide for the issuance of warrants or other rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">(a)<br/>
    Number of Securities to be Issued Upon</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(b)</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(c)<br/>
    Number of<br/>
    Securities<br/>
    Remaining<br/>
    Available For<br/>
    Future<br/>
    Issuance<br/></b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Plan
    Name</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Exercise
    of<br/>
    Outstanding<br/>
    Options <br/>
    (#)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Vesting
    and<br/>
    Settlement of<br/>
    Restricted<br/>
    Stock Units<br/>
    (&#8220;RSUs&#8221;)<br/>
    (#)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Vesting
    and<br/>
    Settlement of<br/>
    Performance<br/>
    Stock Units<br/>
    (&#8220;PSUs&#8221;)<sup>(1)</sup><br/>
    (#)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Weighted-<br/>
    Average<br/>
    Exercise<br/>
    Price of<br/>
    Outstanding<br/>
    Options<br/>
    ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Under
    Equity<br/>
    Compensation Plans<br/>
    (Excluding<br/>
    Securities<br/>
    Reflected in<br/>
    Columns (a))<sup>(2)</sup><br/>
    (#)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Equity Compensation
    Plans Approved by Stockholders</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 40%"><span style="font-family: Times New Roman, Times, Serif">2019
    Plan</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,820</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">39,518</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,475</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">120.71</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">395,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">2012 Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,300</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">309.77</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">2009 Plan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,460</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">310.43</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Equity
    Compensation Plans Not Approved by Stockholders</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">None</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The actual number of PSUs that will vest will be between
    zero and 14,475 depending on the Company&#8217;s achievement of certain performance goals.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of remaining shares of common stock available
    for future issuance is based on an assumption that the maximum performance goals for PSUs were achieved, where applicable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 20 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item
13. Certain Relationships and Related Transactions, and Director Independence </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Policy
Relating to Related Party Transactions </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">We have a
policy that we will not enter into any material transaction in which a director or officer has a direct or indirect financial interest
unless the transaction is determined by our Board of Directors to be fair to us or is approved by a majority of our disinterested directors
or by our stockholders, as provided for under Nevada law. Generally, our Board of Directors as a whole, other than an affected director,
if applicable, determines whether a director or officer has a direct or indirect (<i>i.e.</i>, any) financial interest in a transaction
deemed material based upon our Code of Conduct and Ethics and Nevada law. From time to time, our Audit Committee, in accordance with
its charter, will also review potential conflict of interest transactions involving members of our Board of Directors and our executive
officers. The policy with respect to such transactions is provided in our company&#8217;s Code of Conduct and Ethics.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Related
Party Transactions </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Other than
compensation arrangements, we describe below transactions and series of similar transactions, since January 1, 2022, to which we were
a party or will be a party, in which:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            amounts involved exceeded or will exceed $120,000; and</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            of our directors, executive officers, or holders of more than 5% of our voting securities,
                                            or any member of the immediate family of the foregoing persons, had or will have a direct
                                            or indirect material interest.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Compensation
arrangements for our directors and NEOs are described elsewhere in this annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Agreements
with Rubric Capital Management LP </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">On August
23, 2022, we appointed Mr. Justin Roberts as a director to fill a newly created vacancy on the Board of Directors. As a director of the
Company, Mr. Roberts is entitled to receive compensation in the same manner as our other non-employee directors, but he has elected not
to receive any compensation for his service as a non-employee director at this time. Mr. Roberts currently serves as a Partner of Rubric.
On July 29, 2022, September 30, 2022, October 28, 2022 and May 1, 2023, we entered into subscription agreements with Rubric. On December
30, 2022, and in accordance with the terms of the Certificate of Designation, the Company redeemed all 29,000 outstanding shares of the
Company&#8217;s Series A Preferred Stock from Rubric at a purchase price of $1,333 per share. The Company also paid certain affiliates
of Rubric approximately $3.0 million as a make-whole payment pursuant to the subscription agreements previously entered into between
the Company and Rubric. On June 29, 2023, we issued and sold 312,525 shares of Common Stock to Rubric at a price per share equal to $3.6797
pursuant to the subscription agreement and received gross proceeds of $1.15 million before expenses. On November 15, 2023, Rubric drew
down an additional 877,192 shares of Common Stock at a price per share equal to $2.2761. We received gross proceeds of $2.0 million from
the drawdown before expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 21 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Independence
</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">See <i>Item
10 - Directors, Executive Officers and Corporate Governance</i> above for a discussion on director independence.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item
14. Principal Accountant Fees and Services </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Aggregate
fees billed to our company for the fiscal year ended December 31, 2023 and 2022 by Berkowitz Pollack Brant, Advisors + CPAs and Grant
Thornton were as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023
    (Berkowitz)<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022
    (Grant<br/> Thornton)<br/> ($)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Audit
    fees</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">186,575</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">560,923</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Audit-related
    fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">65,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Tax
    fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">242,301</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">All
    other fees</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">186,575</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">868,224</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audit fees consist of fees associated with the annual audit, the reviews
of our annual and quarterly reports, and other filings with the SEC as well as comfort letters and consents. Audit-Related Fees consist
of fees for the audit of the financial statements of our former subsidiary vitaCare Prescription Services, Inc. Tax fees included the
preparation of our tax returns and other related services. All Other Fees consist of fees associated with consulting and advisory services.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Audit
Committee Pre-Approval Policies and Procedures </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The charter
of our Audit Committee provides that the duties and responsibilities of our Audit Committee include the pre-approval, or adopting procedures
for pre-approval, of all audit, audit-related, tax, and other services permitted by law or applicable SEC regulations (including fee
and cost ranges) to be performed by our independent auditor. Any pre-approved services that will involve fees or costs exceeding pre-approved
levels will also require specific pre-approval by the Audit Committee. Unless otherwise specified by the Audit Committee in pre-approving
a service, the pre-approval will be effective for the 12-month period following pre-approval. The Audit Committee will not approve any
non-audit services prohibited by applicable SEC regulations or any services in connection with a transaction initially recommended by
the independent auditor, the purpose of which may be tax avoidance and the tax treatment of which may not be supported by the Internal
Revenue Code and related regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">To the extent
deemed appropriate, the Audit Committee may delegate pre-approval authority to the Chairperson of the Audit Committee or any one or more
other members of the Audit Committee provided that any member of the Audit Committee who has exercised any such delegation must report
any such pre-approval decision to the Audit Committee at its next scheduled meeting. The Audit Committee will not delegate to management
the pre-approval of services to be performed by the independent auditor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Our Audit
Committee requires that our independent auditor, in conjunction with our Chief Financial Officer, be responsible for seeking pre-approval
for providing services to us and that any request for pre-approval must inform the Audit Committee about each service to be provided
and must provide detail as to the particular service to be provided.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">All of the
services provided by our independent registered public accounting firm described above were approved by our Audit Committee pursuant
to our Audit Committee&#8217;s pre-approval policies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 22 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
IV </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Item
15. Exhibits and Financial Statement Schedules </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            statements and financial statements schedules</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt"><span style="font-family: Times New Roman, Times, Serif">(1)
All financial statements are omitted for the reason that they are not required, or the information is otherwise supplied in Item 8. &#8220;Financial
Statements and Supplementary Data&#8221; in the Original Form 10-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt"><span style="font-family: Times New Roman, Times, Serif">(2)
No financial statement schedules are included because such schedules are not applicable, are not required, or because required information
is included in the consolidated financial statements or notes thereto contained in the Original Form 10-K.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr>
    <td style="vertical-align: top; width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits
    </b></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt; text-align: left; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt; width: 90%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000101968709002459/croff_8k-ex0201.htm"><span style="font-size: 10pt">Agreement
    and Plan of Reorganization, dated July 6, 2009, among Croff Enterprises, Inc., AMHN Acquisition Corp., America&#8217;s Minority Health
    Network, Inc., and the Major Shareholders(1)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510138955/dex101.htm"><span style="font-size: 10pt">Agreement
    and Plan of Reorganization, dated June 11, 2010, among AMHN, Inc., SHN Acquisition Corp., Spectrum Health Network, Inc., and the
    Sole Shareholder of Spectrum Health Network, Inc.(2)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000135601808000256/ex332.htm"><span style="font-size: 10pt">Croff
    Enterprises, Inc. Plan of Corporate Division and Reorganization, dated October 25, 2007(3)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111001316/ex-10_01.htm"><span style="font-size: 10pt">Agreement
    and Plan of Merger, dated July 18, 2011, among vitaMedMD, LLC, AMHN, Inc., and vitaMed Acquisition, LLC(4)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5***+</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459022009476/txmd-ex21_221.htm"><span style="font-size: 10pt">Stock
    Purchase Agreement, dated March 6, 2022, by and between TherapeuticsMD, Inc. and GoodRx, Inc.(5)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex34.htm"><span style="font-size: 10pt">Articles
    of Conversion of AMHN, Inc. filed in the State of Nevada, dated July 20, 2010(6)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex35.htm"><span style="font-size: 10pt">Articles
    of Incorporation of AMHN, Inc. filed in the State of Nevada, dated July 20, 2010(6)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312523211458/d499757dex31.htm"><span style="font-size: 10pt">Composite
    Amended and Restated Articles of Incorporation of the Company, as amended(7)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312510149198/ddef14c.htm"><span style="font-size: 10pt">Bylaws
    of the AMHN, Inc.(8)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713115003704/ex3-1.htm"><span style="font-size: 10pt">First
    Amendment to Bylaws of the Company, dated December 17, 2015(9)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459022022465/txmd-ex31_10.htm"><span style="font-size: 10pt">Second
    Amendment to Bylaws of the Company, adopted May 27, 2022(10)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex32.htm"><span style="font-size: 10pt">Third
    Amendment to Bylaws of the Company, dated July 29, 2022(11)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459022018687/txmd-ex31_8.htm"><span style="font-size: 10pt">Certificate
    of Change to Articles of Incorporation of the Company(12)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex31.htm"><span style="font-size: 10pt">Certificate
    of Designation, Preferences and Rights of Series A Preferred Stock (11)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000166/ex4-2.htm"><span style="font-size: 10pt">Form
    of Certificate of Common Stock(14)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex42_160.htm"><span style="font-size: 10pt">Description
    of Securities of the Company(15)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_3.htm"><span style="font-size: 10pt">Form
    of Common Stock Purchase Warrant(16)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713111002213/ex-10_2.htm"><span style="font-size: 10pt">Form
    of Non-Qualified Stock Option Agreement(16)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119004545/ex99-1.htm"><span style="font-size: 10pt">TherapeuticsMD,
    Inc. 2019 Stock Incentive Plan(17)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312521116458/d152560ddef14a.htm#tx152560_61"><span style="font-size: 10pt">First
    Amendment to the TherapeuticsMD, Inc. 2019 Stock Incentive Plan(18)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113003145/ex10-34.htm"><span style="font-size: 10pt">Amended
    and Restated 2012 Stock Incentive Plan(19)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312513399924/d611784dex991.htm"><span style="font-size: 10pt">2009
    Long Term Incentive Compensation Plan, as amended(20)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120004409/txmd-def14a_061820.htm#txmd_027"><span style="font-size: 10pt">TherapeuticsMD,
    Inc. 2020 Employee Stock Purchase Plan(21)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713112000490/ex-10_3.htm"><span style="font-size: 10pt">Form
    of Common Stock Purchase Warrant, dated February 24, 2012(22)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713113000292/ex10_1.htm"><span style="font-size: 10pt">Common
    Stock Purchase Warrant, issued to Plato &amp; Associates, LLC, dated January 31, 2013(23)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex4-1.htm"><span style="font-size: 10pt">Form
    of Warrant to Purchase Common Stock, dated August 5, 2020(24)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex4-2.htm"><span style="font-size: 10pt">Amendment
    to Company Warrant issued by the Company to the Subscribers party to that certain Subscription Agreement, dated as of August 5, 2020,
    dated November 8, 2020(25)</span></a></span></td></tr>

<tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713121003140/ex10-12.htm"><span style="font-size: 10pt">Second
    Amendment to Company Warrant issued by the Company to the Subscribers party to that certain Subscription Agreement, dated as of August
    5, 2020(26)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713121003140/ex10-13.htm"><span style="font-size: 10pt">Warrant
    issued by the Company to Robert Finizio(26)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713121003140/ex10-14.htm"><span style="font-size: 10pt">Amendment
    to Warrant issued by the Company to Robert Finizio(26)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713121003140/ex10-15.htm"><span style="font-size: 10pt">Warrant
    issued by the Company to John C.K. Milligan, IV(26)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713121003140/ex10-16.htm"><span style="font-size: 10pt">Amendment
    to Warrant issued by the Company to John C.K. Milligan, IV(26)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120007144/ex10-5.htm"><span style="font-size: 10pt">Subscription
    Agreement, dated August 5, 2020, by and among TherapeuticsMD, Inc. and the Subscribers identified on the Schedule of Subscribers
    attached thereto(24)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18***</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713118005976/ex10-1.htm"><span style="font-size: 10pt">License
    Agreement, dated July 30, 2018, by and between TherapeuticsMD, Inc. and The Population Council, Inc.(27)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19***</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119008469/ex10-2.htm"><span style="font-size: 10pt">Lease,
    dated October 5, 2018, by and between 951 Yamato Acquisition Company, LLC and TherapeuticsMD, Inc.(28)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20***</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713119005935/ex10-3.htm"><span style="font-size: 10pt">License
    and Supply Agreement, dated June 6, 2019, by and between TherapeuticsMD, Inc. and Theramex HQ UK Limited(29)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000138713120009695/ex10-3.htm"><span style="font-size: 10pt">Form
    of Indemnification Agreement between TherapeuticsMD, Inc. and each of its executive officers and directors(25)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459022011525/txmd-ex1055_277.htm"><span style="font-size: 10pt">2022
    Executive Retention and Performance Bonus Plan. (ERB-Plan)(30)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex101.htm"><span style="font-size: 10pt">Subscription
    Agreement between TherapeuticsMD, Inc. and Rubric Capital Management LP, dated July 29, 2022(11)</span></a></span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 23 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 90%"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522207645/d356180dex102.htm"><span style="font-size: 10pt">Subscription
    Agreement by and among TherapeuticsMD, Inc., Sixth Street Specialty Lending, Inc., TOP IV Talents, LLC and TOA Talents, LLC, dated
    July 29, 2022(11)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522256102/d378570dex101.htm"><span style="font-size: 10pt">Subscription
    Agreement between TherapeuticsMD, Inc. and Rubric Capital Management LP, dated September 30, 2022(31)</span></a></span></td></tr>

<tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522256102/d378570dex102.htm"><span style="font-size: 10pt">Subscription
    Agreement by and among TherapeuticsMD, Inc., Sixth Street Specialty Lending, Inc., TOP IV Talents, LLC and TAO Talents, LLC, dated
    September 30, 2022(31)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522273110/d394277dex101.htm"><span style="font-size: 10pt">Subscription
    Agreement between TherapeuticsMD, Inc. and Rubric Capital Management LP, dated October 28, 2022(32)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522273110/d394277dex102.htm"><span style="font-size: 10pt">Subscription
    Agreement by and among TherapeuticsMD, Inc., Sixth Street Specialty Lending, Inc., TOP IV Talents, LLC and TAO Talents, LLC, dated
    October 28, 2022(32)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29***+</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-left: -0.125in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522298002/d409080dex101.htm"><span style="font-size: 10pt">License
    Agreement by and between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated December 4, 2022(33)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30***+</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312522298002/d409080dex102.htm"><span style="font-size: 10pt">Transaction
    Agreement by and between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated December 4, 2022(33)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31**</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex1045_158.htm"><span style="font-size: 10pt">Amendment
    No. 1 to the License Agreement between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated as of December 30, 2022(15) </span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex1046_159.htm"><span style="font-size: 10pt">Amendment
    No. 1 to the Transaction Agreement between TherapeuticsMD, Inc. and Mayne Pharma LLC, dated as of December 30, 2022(15) </span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex1047_471.htm"><span style="font-size: 10pt">Amended
    and Restated Employment Agreement, dated as of December 18, 2018, by and between TherapeuticsMD, Inc. and Marlan Walker(15) </span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000156459023005514/txmd-ex1048_439.htm"><span style="font-size: 10pt">Amendment,
    effective October 15, 2021, to the Employment Agreement, dated as of December 18, 2018, by and between TherapeuticsMD, Inc. and Marlan
    Walker (15)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312523050813/d372195dex101.htm"><span style="font-size: 10pt">Amendment,
    dated February 21, 2023, to the Employment Agreement, dated as of December 18, 2018, as extended effective October 15, 2021, by and
    between TherapeuticsMD, Inc. and Marlan Walker(34) </span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312523050813/d372195dex102.htm"><span style="font-size: 10pt">General
    Consulting and Services Agreement by and between TherapeuticsMD, Inc. and MCD Consulting Management Services, LLC, dated February
    21, 2023(34) </span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312523147098/d256418ddef14a.htm#tx256418_63"><span style="font-size: 10pt">Subscription
    Agreement, dated May 1, 2023, between TherapeuticsMD, Inc. and Rubric Capital Management LP(35) </span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38*</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000119312523277143/d569965dex101.htm"><span style="font-size: 10pt">Master
    Services Agreement, dated August 15, 2023, between TherapeuticsMD, Inc. and JZ Advisory Group (36)</span></a></span></td></tr>

  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000121390024028003/ea020146501ex21-1_therapeu.htm"><span style="font-size: 10pt">Subsidiaries
    of the Company&#160;(37)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000121390024028003/ea020146501ex23-1_therapeu.htm"><span style="font-size: 10pt">Consent
    of Berkowitz Pollack Brant (37)</span></a></span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000121390024028003/ea020146501ex23-2_therapeu.htm"><span style="font-size: 10pt">Consent
    of Grant Thornton LLP (37)</span></a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1&#8224;</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020482901ex31-1_therapeu.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) (42)</a>&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2&#8224;</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020482901ex31-2_therapeu.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) (42)</a>&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000121390024028003/ea020146501ex32-1_therapeu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 1350 Certification of Chief Executive Officer&#160;(37)</span></a></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/25743/000121390024028003/ea020146501ex32-2_therapeu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 1350 Certification of Chief Financial Officer&#160;(37)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/25743/000121390024028003/ea020146501ex97-1_therapeu.htm"><span style="font-size: 10pt">TherapeuticsMD,
    Inc. Policy on Recoupment of Incentive Compensation (37)</span></a></span></td></tr>

<tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase
    Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase
    Document.</span></td></tr>

<tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104&#8224;</span></td>
    <td style="vertical-align: bottom; font-size: 10pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; font-size: 10pt; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL for the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set</span></td></tr>
  </table><div>
</div><p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Indicates
                                            a contract with management or compensatory plan or arrangement.</span></td>
</tr>
<tr>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: left; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    confidential material contained in the document has been omitted and filed separately with the Securities and Exchange Commission.
    Confidential treatment has been granted with respect to this omitted information.</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td>
    <td style="text-align: left; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portions
    of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(2). The omitted inform harm to the Company if publicly
    disclosed</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="text-align: left; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    of the exhibits and schedules to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Company
    agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="text-align: left; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;&#8224;</span></td>
    <td style="text-align: left; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
    herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Filed
                                            as an exhibit to Form 8-K filed with the Commission on July 10, 2009 and incorporated herein
                                            by reference (SEC File No. 000-16731).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Filed
                                            as an exhibit to Form 8-K filed with the Commission on June 14, 2010 and incorporated herein
                                            by reference (SEC File No. 000-16731).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Filed
                                            as an exhibit to Form 10-K for the year ended December 31, 2007 filed with the Commission
                                            on May 1, 2008 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Filed
                                            as an exhibit to Form 8-K filed with the Commission on July 21, 2011 and incorporated herein
                                            by reference (SEC File No. 000-16731).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 24 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Filed
                                            as an exhibit to Form 8-K filed with the Commission on March 10, 2022 and incorporated herein
                                            by reference (SEC File No. 001-00100).</span></td></tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Filed
                                            as an exhibit to Form 10-Q for the quarter ended June 30, 2010 filed with the Commission
                                            on August 3, 2010 and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(7)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Filed
                                            as an exhibit to Form 10-Q for the quarter ended June 30, 2023 filed with the Commission
                                            on August 14, 2023 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(8)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Definitive 14C Information Statement filed with the Commission on June 29, 2010
                                            and incorporated herein by reference (SEC File No. 000-16731).</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(9)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on December 22, 2015 and incorporated herein
                                            by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(10)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on June 3, 2022 and incorporated herein by
                                            reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(11)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on August 1, 2022 and incorporated herein by
                                            reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(12)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on May 9, 2022 and incorporated herein by reference
                                            (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(13)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on July 6, 2023 and incorporated herein by
                                            reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(14)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form S-3 filed with the Commission on January 25, 2013 and incorporated hereby
                                            by reference (SEC File No. 333-186189).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(15)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 10-K for the year ended December 31, 2022 filed with the Commission on April
                                            7, 2023 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(16)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on October 11, 2011 and incorporated herein
                                            by reference (SEC File No. 000-16731).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(17)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form S-8 filed with the Commission on June 21, 2019 and incorporated herein by
                                            reference (SEC File No. 333-232268).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(18)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            appendix to the Definitive Proxy Statement filed with the Commission on April 14, 2021 and
                                            incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(19)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on August 22, 2013 and incorporated herein
                                            by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(20)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Registration Statement on Form S-8 filed with the Commission on October 15, 2013
                                            and incorporated herein by reference (SEC File No. 333-191730).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(21)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            appendix to the Definitive Proxy Statement filed with the Commission on May 4, 2020 and incorporated
                                            herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(22)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on February 24, 2012 and incorporated herein
                                            by reference (SEC File No. 000-16731).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(23)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on February 6, 2013 and incorporated herein
                                            by reference (SEC File No. 000-16731).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(24)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 10-Q for the quarter ended June 30, 2020 filed with the Commission on August
                                            7, 2020 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(25)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 10-Q filed with the Commission on November 9, 2020 and incorporated herein
                                            by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 25 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(26)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 10-K for the year ended December 31, 2020 filed with the Commission on March
                                            4, 2021 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(27)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 10-Q for the quarter ended September 30, 2018 filed with the Commission on
                                            November 8, 2018 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(28)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 10-Q for the quarter ended September 30, 2019 filed with the Commission on
                                            November 8, 2019 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(29)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 10-Q for the quarter ended June 30, 2019 filed with the Commission on August
                                            9, 2019 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(30)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 10-K for the year ended December 31, 2021, filed with the Commission on March
                                            23, 2022 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(31)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on October 3, 2022 and incorporated herein
                                            by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(32)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on October 31, 2022 and incorporated herein
                                            by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(33)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on December 5, 2022 and incorporated herein
                                            by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(34)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 8-K filed with the Commission on February 27, 2023 and incorporated herein
                                            by reference (SEC SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(35)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            appendix to the Definitive Proxy Statement filed with the Commission on May 17, 2023 and
                                            incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(36)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 10-Q for the quarter ended September 30, 2023, filed with the Commission
                                            on November 14, 2023 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif">(37)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed as an
                                            exhibit to Form 10-K for the year ended December 31, 2023, filed with the Commission on March
                                            29, 2024 and incorporated herein by reference (SEC File No. 001-00100).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 26 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized, on April 29, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>THERAPEUTICSMD,
INC. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Marlan D. Walker</span></td>
    <td style="padding-bottom: 1.5pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">Marlan D. Walker</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">24</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-5548">true</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-5549">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-5550">0000025743</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="txmd-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbcL4qf5LvDZDepCbNlW2HHdtTp8h/JBPAKml91Z9+QS2gjfdoyURiOQgrxFESWde/Q+Ash/YJdGlbG5QR3nEMX5o5KwxkMj+eXHxJunE3ZaqLj0+u3xzOW4EnF5nj3k6T33Tr1iNLEtTKJ790yb+Z3jwZkvL/UozZI5coydP07aTHqbQBuZ+yoAa5uW0u87LGWKivro80zG7sY1mWte3vH] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ea020482901ex31-1_therapeu.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; margin: 0pt 0"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Marlan D. Walker, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K/A of TherapeuticsMD,
Inc.;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: left">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(3)</TD>
    <TD>[Omitted];</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(4)</TD>
    <TD>[Omitted]; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(5)</TD>
    <TD>[Omitted].</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: April 29, 2024</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">/s/ Marlan D. Walker</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Marlan D. Walker</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ea020482901ex31-2_therapeu.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; margin: 0pt 0"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Joseph Ziegler, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K/A of TherapeuticsMD,
Inc.;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: left">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(3)</TD>
    <TD>[Omitted];</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(4)</TD>
    <TD>[Omitted]; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(5)</TD>
    <TD>[Omitted].</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: April 29, 2024</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">/s/ Joseph Ziegler</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Joseph Ziegler</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Principal Financial and<BR>
Accounting Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  D /L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^S?\ :R_:
M]^"_[%/PVL?BW\<M4UG3?".I>+-,\%V5WX?T&;Q#J0UC6PWD*T<?!B;^R)"Y
MR#Q'A)"%,7YYC_@X._X)NPCY_'7CV#I_Q\_#;6X\$'CHQZ'T^E?L;XP\$>%/
M&^EPZ5XO\/Z+XBL8+A+Q+/7;)-0L$U 9VN$E#+E2Y'S)@#:I7(P/YNO^"X?P
MD^&WAKQY_P $R+?P_P" _"6CV^N?ME:/8:O;:7HVBZ8VHZ8%T$OI+;51?F.,
MA1A2IP!G!]C)J&4XO%?4\6WK=WBTK6C*5W>[LVK:=6EYKXOB+$\085?6L&XV
M;2LTNK2:3T77R/T'^#7_  6M_8:^/OQ5\#_!_P"'/B7Q[J'C?XB:O_8GARUU
M7P%K&FZ>VI*.$>5R<#/S,2">,[ADU[)^RE^WYX-_:A^.7[4/P'T;P%XG\*:O
M^RQXS7P3XB\0Z[JND7^F>*M0 XU70O("MY8.YBTA8 LP9L;0/J+1?@C\(/#M
M]9:YH7PV\!Z9K.FH;JSU32/#6C:9J.GDC&Y9(T$JD9/S!QM(& K $?R._LO_
M +2OQN^#7_!07_@IM\+/V9_@K/\ &/XX_$[X]:I?Z):7MX--\#>$/#.AZR8]
M=UKQOKIQAB'*C')S@=:Z<-EN#Q>&S3ZHFO9J\7*2W<G%WLTKJ*ZZ)[6;N<F8
MYSFN68G*OKMFIKWE&-]'%-[*^MW>VZ/[01=0#/4Y^@_K5GS8?\G_ .O7\XOP
MQ_X*D_M>_ C]ISX4?LZ?\%%_@3X2^&^C_'C61X8^%GQ8^'MZ=3\,#Q1K9_XD
M6B:V#D Y)#$#/KG"X^W_ /@H-_P45M_V/I_AO\+/AQX NOC'^TM\<-7;0_A!
M\)])O2CWIR5;6==((*^'T.X':P96'4'FO&628QXM6L[K2VJ:25[-732TO9L]
MNAQ)E/U1R=TU\2:2U=WJG:VJ=E_F?JD=1R,& _E_@?YYH^UC'GXXZ8SQZ9S_
M )]*_G%\=?\ !0__ (*8_LCZ9H/Q=_;0_9A\ 7?[/]U>:9I_C'5OA-K9U3Q+
MX".LL5;6=<7)5?#ZN2LA #Y 5S\H"_6W_!13_@I&O[)G[,'P2_:2^%=KX<\:
M>#_BY\2OA?H]I?:HQ33+/P+X[0ZS_;>Y&#$B,*,Y!'RXRRY LES5XM13BXRO
M&-K-/1W5TVMM=^_56;_UKRE81XIIJVC35FM;;.SM9Z:'[&+?P+_$3^'^?;\J
MA^V6_H?S_P#KU^$?[-__  4:_:U_;"_: \'7OP5_9>;3OV)[G5_L'B/X\^+G
M.G:KX@TL XUG0]$=LOX?(!Y)R>K'J:L?%?\ :H_X*T>(/B7\0?#?[/G[&O@C
M3? '@+Q'JFB:3XK^)WB;:?'BZ,=HUG1,," [#"^K#Y3D5O7R;$X:7U1N*DDG
M*THR:OK9Z^O9VU\PK\0X18-8M*5GM:,FVM[I6N]-][>MS]TI]1\H?ZGI[G/\
MQQ]>G;TI(=1AF$X\HYMN2< \?B._K],U^+G[!G_!2CQ_\<_CA\0/V/?VJ/@V
M_P #/VGO 7AP>)SH]E=M)X<\7>%F8*=;T(DEL+NW,><(O'%?$7A/_@M%^TE\
M3/B]^T#^S9\'?V9K?XD?'CP'\5=6\&^ [32V;3_#.G^%]$9M$/C3QQKK%L $
MD*N=J+A%4*% K#Y-B\3S)V3BKMOW4EK9N^BORN^JM:[.;_7/*?JJDD[O1;ZM
M?W=7I?\ EZZ7UM_40+J";_ED>1WP/IGC_/3.#@N^UP>_YCW]_I^7O7\VEY_P
M5/\ VYOV.?&7@>?_ (*._LW>%/#7P/\ 'FLKHG_"X_A-?'4],\):IK1/]A+K
M@;*KGE7( ;U.Y01^G'[9G_!0+X5?L=? '2/CMJL5UXW/Q#O=*T3X6>%/#I!U
M3QYXHUU0="T31>,<J1VS@DC;FN:OEF:)J,6K-V7+[R=KMV:<KZ7V?RT9TKB/
M*?JOUJUG=7NM5>VK3U6O='Z*?VC;^II/MF>__CM?SAZ[^W'_ ,%A/!'@&W_:
M%\8?L7_#<_"&ULCXFUCX=Z3KC-\2]!\+A]S'RRQ3<OAXG+8W*#M+8XKZ&^/_
M /P5=\/Z3_P32/\ P4'_ &>](TSQ;:O=^&[)O"GB E6T+4Y-<71/$.B:X5(*
M^(?"[YW ,N2HX(/'1_9&,LG>^J5T[KFM>SLVD]'H[;;"_P!9<$U:Z5UU=MUY
MM=S]K/M<'E YZ$CZY)X]<C\O>D-_N!$4)8'GT[@\'_'\NF/-_A-XLG^('PO^
M''CB^@M[74/&7@_POXGN[2U/%B=>T5== !R3RS!>G)S@$8S^6_P;_;P^-_QQ
M^*'_  4=^$?@#X<^'+KQA^R;XFTWPO\ "NU^V-_Q76I[68G6VSE?N]<X' ZX
MKGAAL1B&XIJ*4HJ3V2O.*NV_AU>]U;>]D;U,R6%AES;34H3DEH^9<DI::Z[?
M9OV/TD^&/[2GP8^,VO?$?PI\,_'&E>+/$'PD\2GPK\1M+TIRTGA/Q-L(_L;6
MR54)*>2P7>"%)).,#R7]L+]N7X.?L6:5\,-4^+EGXTNK?XL^/!\/?#G_  B7
MAQO$3)JK*[%]9VNI@T7$N[S5)DP<@+NK^4;_ ()M?&#_ (*2^%OC[_P4'OO@
M%^SG\-O&WCCQ1^TCJ>M?&S2M7\2?V9IGA+Q]G7CK>BZ&1CDG'KG@<YK]Z/\
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M5U%*]U?1122>_;7KY7/S6_X.#K2"*/\ X)T7D,'^DV?[:_@'[)=C_EQ/]LZ
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M_!7_  16O(/^&OO^"P$/G_9[BY_; U4CZ_VSX@Z9[D9'4<$\UO\ _!P3Y_\
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0K_-BQ.S^?_MQ8HHHI#/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>txmd-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 29 18:38:14 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://www.therapeuticsmd.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:txmd="http://www.therapeuticsmd.com/20231231" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="txmd-20231231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="txmd-20231231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="txmd-20231231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbcL4qf5LvDZDepCbNlW2HHdtTp8h/JBPAKml91Z9+QS2gjfdoyURiOQgrxFESWde/Q+Ash/YJdGlbG5QR3nEMX5o5KwxkMj+eXHxJunE3ZaqLj0+u3xzOW4EnF5nj3k6T33Tr1iNLEtTKJ790yb+Z3jwZkvL/UozZI5coydP07aTHqbQBuZ+yoAa5uW0u87LFeZ+HnVBnz0xvbGHH1fvD7] CSR-->
      <link:roleType roleURI="http://www.therapeuticsmd.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="txmd_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>txmd-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 29 18:38:14 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#DocumentAndEntityInformation" roleURI="http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbcL4qf5LvDZDepCbNlW2HHdtTp8h/JBPAKml91Z9+QS2gjfdoyURiOQgrxFESWde/Q+Ash/YJdGlbG5QR3nEMX5o5KwxkMj+eXHxJunE3ZaqLj0+u3xzOW4EnF5nj3k6T33Tr1iNLEtTKJ790yb+Z3jwZkvL/UozZI5coydP07aTHqbQBuZ+yoAa5uW0u87LFqZpCDsFbVP40cvtWLaehe] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="39" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>txmd-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 29 18:38:14 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbcL4qf5LvDZDepCbNlW2HHdtTp8h/JBPAKml91Z9+QS2gjfdoyURiOQgrxFESWde/Q+Ash/YJdGlbG5QR3nEMX5o5KwxkMj+eXHxJunE3ZaqLj0+u3xzOW4EnF5nj3k6T33Tr1iNLEtTKJ790yb+Z3jwZkvL/UozZI5coydP07aTHqbQBuZ+yoAa5uW0u87LHs9LPNfd9IPN+RGqKhM4tB] CSR-->
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>txmd-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 29 18:38:14 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="txmd-20231231.xsd#DocumentAndEntityInformation" roleURI="http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.therapeuticsmd.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="txmd-20231231.xsd#txmd_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbcL4qf5LvDZDepCbNlW2HHdtTp8h/JBPAKml91Z9+QS2gjfdoyURiOQgrxFESWde/Q+Ash/YJdGlbG5QR3nEMX5o5KwxkMj+eXHxJunE3ZaqLj0+u3xzOW4EnF5nj3k6T33Tr1iNLEtTKJ790yb+Z3jwZkvL/UozZI5coydP07aTHqbQBuZ+yoAa5uW0u87LE0f3yt5uIzYpkVv3T95d4u] CSR-->
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140472283216592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 19, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERAPEUTICSMD,
INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,532,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,439,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This
Amendment No. 1 on Form 10-K/A, or the Form 10-K/A, is being filed by TherapeuticsMD, Inc., or the Company, in order to disclose information
required by Items 10, 11, 12, 13 and 14 of Part III of Form 10-K, which information was omitted from the Company&#8217;s Form 10-K for
the fiscal year ended December 31, 2023 (the &#8220;Original Form 10-K&#8221;), in reliance on Instruction G to Form 10-K. The Original
Form 10-K was filed with the Securities and Exchange Commission, or SEC, on March 29, 2024. The
Company does not expect to file its definitive proxy statement for its upcoming annual stockholders&#8217; meeting within 120 days of
the end of its most recent fiscal year (as required under Instruction G to Form 10-K). Therefore, the Company is filing this Form 10-K/A
in order to include information that would have been contained in the definitive proxy statement into the Original Form 10-K. The Company
is also filing as exhibits to this Form 10-K/A new certifications with respect to this filing by its principal executive officer and
principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002; accordingly, Item 15 of Part IV has also been
amended to reflect the filing of these new exhibits. Because no financial statements are being filed in this Form 10-K/A, and this Form
10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications
have been omitted. The Company is also not filing new certifications required under Section 906 of the Sarbanes-Oxley Act of 2002, since
no financial statements are being filed with this Form 10-K/A. Finally, the Company is filing this Form 10-K/A to delete the reference
on the cover of the Original Form 10-K to the incorporation by reference of portions of its definitive proxy statement into Part III
of the Original Form 10-K.&#160;This
Form 10-K/A is limited in scope to the items identified above and should be read in conjunction with the Original Form 10-K and the Company&#8217;s
other filings with the SEC. This Form 10-K/A does not reflect events occurring after the filing of the Original Form 10-K or modify or
update those disclosures affected by subsequent events. Consequently, all other information is unchanged and reflects the disclosures
made at the time of the filing of the Original Form 10-K.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-00100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0233535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">951 Yamato Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">961-1900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Miami, Florida<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MI=:&U80!@=UIGXYO']"HB*F$R'<D)5&Y!!6?[GH,LD=OY\1T&@6X4FM#:Z*
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    "  $B)U8!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  2(
MG5CKA;6J[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    (  2(G5B97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ !(B=6&J4"8/&
M"P  V3T  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    (  2(G5BV,20+[@(  (D.   -              "
M 0D4  !X;"]S='EL97,N>&UL4$L! A0#%     @ !(B=6)>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  *<;      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>39</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>2</UnitCount>
  <MyReports>
    <Report instance="ea0204829-10ka1_therapeu.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.therapeuticsmd.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K/A" isDefinitelyFs="true" isOnlyDei="true" original="ea0204829-10ka1_therapeu.htm">ea0204829-10ka1_therapeu.htm</File>
    <File>txmd-20231231.xsd</File>
    <File>txmd-20231231_def.xml</File>
    <File>txmd-20231231_lab.xml</File>
    <File>txmd-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0204829-10ka1_therapeu.htm": {
   "nsprefix": "txmd",
   "nsuri": "http://www.therapeuticsmd.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ea0204829-10ka1_therapeu.htm"
     ]
    },
    "schema": {
     "local": [
      "txmd-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "txmd-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "txmd-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "txmd-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 39,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 42,
   "unitCount": 2,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 39
   },
   "report": {
    "R1": {
     "role": "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204829-10ka1_therapeu.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0204829-10ka1_therapeu.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "txmd_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.therapeuticsmd.com/20231231",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r7"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r5"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.therapeuticsmd.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-24-037258-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-037258-xbrl.zip
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M<5\F^ >QL:&6.X@E+O9&?(E"L3^.16=/M'??='??M#?%U\L#T6EU-OGQ80I
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M[=;;7U_C]]^IO<]@X/4,"NY YY*@F3Z4\7W/7A\)G85HO15(=1MNX%_!G_I
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M?NW%K]_!%6PQ"#T;7[FA_Q_Z_55ANU/44$Z83T>-SX34X^9Y\Z(ICD;C()H
M5HNT*$ZBY@S6%%&\)AFNY/H/I-14[6IZF!!:)I'<4Z+M>UXLDT3]Y[,?RG;!
M4MA[\6YOJRW^<.'NBP *UWM$&&?>*SOV*[NM%^\N,A^D1Z<SXWZZOU!8QFWU
M('&PA!,N>V^YE%_:]5@):CR 'T_CR^@F+!!&^\6[]U'?%>= BN&]R?#>^IL"
MAFZRT_@,GO0I6]N""#2W#T$4^ZAM+4ZH]]*V5D:TRR29!YWR601'$/S#'T_I
MP[OM)1-AM[N)T><UTIX4AM!_,8Z!ZORQ&PCY7?:SU+]&MP;<^3)Y2A6IHAH1
M4(] \GF0WE,-E]4Z^27O)]-1C._'TBWR-XC-[HMW6]LS^2 ;"R_\&6Z!X&P8
MA271J^XF:"S;[8WVWFSP:MT\F;GO\K_^M-MI[[Q-G%0&<HP[%R%MO8%65)#A
M?2)<P#5@#;AAK:H%UHX!+D .QW[JR\2)Z81D+#TQSN(D0S<SZ,GP!%ED[<[+
MWBN4XA@ZW^\#^#^\F[D"%ME=5^#CM"!M5MQBU767ZQG#K!DLW4-".G+[0W$0
MN$ERV^5_"VR=7]9 TWP>',<NB=%D,NI%08W>97NE54!.(@7+[_VA&U[!'T)Q
M,_3A+[DDG:/*Y7S=@PU>Q5$6>B@"HOB-B*]Z+SNMS4:GN]OH;&V]>O% W711
M!43= )-VIT><F2L@G>ZRO?F8ZP-8NDBC_K>&&+NQN':#3(H_MYJM5ANSL$0R
MA*O_/O[^LH,OP5(%K(5%3T0Q[P7QKGT<R_;'7_[]R^&/B>JE8@GTG7OZ8U D
MS+IB-*<=*8$QG<K0W7H!DB7QW']/GP1SC/CBQM]D*CY_/EC$1/R1PK9KKCA?
M%17G$[!Y?GCE^;%']@C(CD,/XTC2Z4U$?RB!<V#E;\+G(XCS+!H_$:ZX 7U^
MXUL8W<"[I)O V7CP09*A0>HFPI,#/^0D&\R-$)NM+7V8.0W@N3;%'_"#2A>_
M;R#A=P#BKPC#A0+AF" HB(=M$ _1C&@P-5G5.X<?@T+"*(6__#OSD<&!KP>8
MI1Q3K4!2SO!=# ";WRCQ/V?_1Y')WZ(@"U,WIG3GN% TU-VIR6/%Y'$SE)0!
M,$4C+]NOQ! D!1*&)]P@,-1ADTU/J@=@S2*E%"C$DBE:3W" :O!C*@WQX%,P
M[/#1<2S[DLR\=D=0@5LB7L)ZH(V() ,[)!E&F!"HJQO2H9M.PW[C)K/$35]6
M>W@%0C#TQ,O.*P?WV .=!C[O_0MV@,_3H_ EA$*M@T4U"0%!0+I)*O9:PG,G
M2?.^Y*XJ\[@P!U7BU$V+I7*H$P,_S2-[N&J%*>"I'IW]*!R E %$,?)3;+0F
M R".. I150\F0H+:/A''J+RX?8KY'+JI*SZP&"TP2+Z&+5?QVG74M7LNK[*
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M@58GQ<O96/HB[K]7Q7CI2;0$<:3L601OQJH"\=.M;\JE0+9/ N&W+)1.M]7
MR3C=QCQ^'T4)<3/(#KB.R"R0:$[ 51N%GFX[^N^,.ISP*N[5%2R$U^B(\Z(X
MEU#1T'5$RABHF[GKG?_&O_<I%=%!:99.!) ""B7+2S_ JQ063\SCXTQ-$8+;
M%2Y[D'-XB>*[U/O'0"( 5JJR0/GRI81']18,&@48#TTB>!W^]F=%S!\H\ -/
M%JBY_0(XIN^/@'[)86R3=IB--KPHW5 /S)+W&2FF'X+(35\(Q)ZD-;+0Y]6S
MQ"M0_>:+=]W-QF9WK]':Z6C"UW"]:U:1P%9.^DS!^W"P@6CO$0EO$O'!U7B#
M_T192K8HDMJM1]FQC_+XY,,]#Y,39RD+\ (39)/3_,6EITMIM(5(^>;6BW?M
M=F.KVVEL;G9G#I@3;[6.Z92PJ*+EY*[DW69^$C\!B:Q5\(>2<^^7;[^BO'K*
MH516J\!$V#</J#*^M7;A&6L4G@)G6#>(C%OC[7YX^X#>F>/#&;3=&52@9//[
MEFLL->OXO8R_13=^^A]QAMP.V'N/ KHA]KUK/XG 1/K?XN!L/UF\U&=E9[W4
M5_T.1J@X<X.1>(\%-PWQX?./ML6MSOUI<0%*6S0!23%'L2"AN_?P\I\7[SZ>
M4QOL3Z?G)Y>G)^+SY[.'5YD\[1G>$VE:$-N(VWD$Q%]\> YH7/?B^"&1AE+X
MV+(_-EN/H;7.YNX"\>*?+BQ8R?&3[?'MXR?->,KEH?8)FP"OCBR6U_[_#LI
MC+R%+_X[0Q<'K)^CAT:P\A?F4 SV]YTAF6V+$N9J?R^>ME!-HWG\+M_0O WV
M8NE^V^A)L-@!'V/"C_V2[9*7J$;'LW-,%WJY3:9K0Z&5+=4[^OO9Y_V3_<O3
M\S^<D]/+HQ^IH\CM]R[^[H>9]/;3O[SXIYGY=RB3?NR/46O9Z+?^B4_]LUVX
MI4N>M"YK+#5:%IYTP_[.)LJ"1R#J<N@GC@%<T%A#3#CX@&/>>6@CY5&C6[;P
M-Q^K6CAPK\IS+JU9X5\.&^(X[#?-=P_R]!A!,@V]P)Z?] ,,H_FA&;WNF% 9
M+'F<RE$"KVR(=AO^WVE@[0_F0K0WT>5VYL:I.#X^QI\-< WE2+;6)*=QI&HD
M:%J)!9+QU)D5T,DX9VR7-<R*7?/B)3ZHTK=/8Q]."KYAEE*9VZ]HW[$,?!SW
MC?@]#I,TSMCE^1%Q8;[21$0*O9230W5C,D,HZV>J[ FQ8B) ^700.H"+HX,&
MOO2+&P-B.LHEVQ0V?TRK@*O@[J51[=WLK7C8-3[E!1E:-:*\B^NKAQ(@&D=1
MM/ BR068\OM859Q1A1JFT>ABAVNLZ(F^3_*<!4HMPT>R<1^8A<) .-20?=?#
M* "N312WB)&4J4Y \S%;@VO5@!.)<P!Y0F4:63&J D.]M&N!.,EH/E.\(JZ(
M29EHV-R+<DBE;U#EDB6C'%O4J)2/@E2@R/Q-E 6>&+J #ZK2PP-V=;C5K@XI
M09@?JE#6+.,S%RL@'0SL!DFD(<7$O^]#OX?HH16*@ M,YNNC\T(W]DV8Y6.9
MZ/.D[ZCE0%#B2O/[!&+2@N?DG^<)*_KSL@R<;JMS2YX7?-)IM3IO*8<K1G]I
M -(=!;9H;^7"^6^4T$:;1_0Z[D@E-D:%=!NU$WX=7 B( 8VBIG@O^RZF1H91
M>88/YES8EQ&=7!&G7(]I_NHH3!M.4<=.)4,((B5:J/LIP[C5%/[Y9NJV=FC=
M;FNW6&8G+O B&KNQ>P5WXA">;(A->M24P1</V,DI4%U4!0H2FH(05H6L$BJ9
MXB=]DGNM[;M/LB$2S$)Q%D6RNH2*:&Z" AYB_>*B3$IJ@,2HM8IQJR"Q$X4J
M%(QYB0KX63;3L>1B(_%"M!D[:&(JHZKNND,&$DMKO<*9^][F[ WT>NK6^;&N
MT+LOQ4XE+T70;FUJ ^(+?. O%A))/QJ;= 2?.-I7#=4Q5:L'M$<\FPSIDN@A
M?;KT3=CQO[*0N<MH8R7DR4)G1M=TN"<^\T1BZ7-'!\CV4RQBA)26F/*:$QO[
MH/U1=I<[2$T&I"5(RR " 3>*/'\P@9^<;(QC7E4N6R[M@-DI9YB5\"3K)>37
MT"]NPG9"]2?D=*S=YPW9MRML C!$^JA'>%#0)WRKYB]S1JY'"2 T7= ?F624
MN_;R]$SX(WFH.L_EH0J11((G&#]4NZB61J+.,@EU^;ZJR_WWGX^<TP_BX/3D
M\NCD\F*MG%6P@07FK#US@@Q0\5TI,DSH*68O(TSA7UYT#4"KGS-@+T9O\V1?
M*81O2!V&RP3V870[YDJ%[)*LAOMLN%B8O.1Y#W/>LKODI)/IU]R25K**@18/
M0'=IGLY*<?+T;WQ(^L^2.0OOJ8=QR&*9/WK+2X2:W1"M9AEFEXD<5PQCC!K\
MR<69NR_>'?I8!Q+%\)TCXX,YU:48Z(1!( Z4J2K%1[1NT=8&!+OO[L>-RSSE
M]D/.=H4GUW[:DP/3-3^N ZOTYIE/I;5V+-=YVH/KOM =12?B]"8$)AOZ8S08
M#P SZ,Y[+T,)W.>[ <'"SY U^L64SM*OYS*@OA<7N:\;'DGA1)-G)H+MBO%F
M]VF/>//%.WV8=$;HQX-#3NQ3(R NL52>T_(3]O9J:2R.0?T;H]_Y^07M[MJQ
M].;3GO<6J.@F4+'/]>$8F/@@59 3EKG&V4?/?)![CV/+-;"1_O9X$^EI2/<V
M/?II+:1G,(M6*NNWGI;WMU$/4W%19/4/)@YU80(T%_VA]++@N?F_4UG=;!7<
M<.?)[8 B!MMT4W3H/_/);):>S!K,@5O,#[@BH.\3.N@^?>C@X9$ :Q]Z!V_%
MY60,^_@<W<B8,/:6J^EHIR<1;L\O^.KU-VGC/VULX8F2-"L=:CC;/[]T,.=P
MI4RZ<BE"_[@4UE>^*Y;:%8 >50^GW6J*.[UII9ZT-3^8YP70H-RI*I#5;=R!
MZ5J#* BB&VP+R.&Z1')3?VP0J+P8=HX$=N*@W#G.=>+>Y<+3AZ!3'U3VR#IV
MDZATU%)W/+U_T.5FZ*=R [<@,:'A)G:M>>^M50S.FS; %PI-Y8A:;:SP447J
MN\M&U_YLO.K'P=;6TJGK+.(.HPNX>.YCO]X:REW>!BZCT6@B/F+:'$C)!+<Q
M'_-/,)=S)EI?)BD6'\>Y3%3MMM<7-\O$P\'0]>$&#@D<=<6^C^ B%K\FV?C=
MR\XK #H;SV.&IZ;P@RC"+D$'F'89!'Z8K.\IKIK"-S?7%S?+Q(-6XQD<(NKV
MJ[OHNL)"_J/K!^*O37'B9E?#%*O:SH;-PU+G]'H<]JH987MW?7&S<D:HE'3_
M+4M2L H_->'Y'KRJEN[SI7NMOSQ4NJ]7%Y=*.PUNR_QM-3M;?KC,LV9QM<I
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M..8)&R:9)!"\-Z,L-@.!J$F/^.).2.;S8$!NJ:%OVV)("WXQ23WFR]0&#EO
M$1B?I#W4+ =BP46IH9X!",?Y!;#5<<J6)[S&0&D5V167)3!X:5IMZNN\I@6V
M^(!/_98%^-).:_J!#N*Z'\O4C2<YAHL;.T8QXH_$62P3:OJ"K<L0#/SP:PA
MQ@F6E0& O_M)'^P];!@S20"N9MGJU)V)7I'DN//E8#9U#9<T7_L4!:BP8\42
M-I5)L@#;JA$@.!&Q*?9Y+<YO8W+(X2%D_>:&&8+2WMO=H:9ILA?3'SJM5KL4
M$]A)<"SC(:COHH=MXK^%T4U(_=^P]XP<8,92PMB(:*9H"I+H/]RB*7\[#AF*
M1I.&^6)($@#LT4"ZGB[&@]?)8,!CT5!*<&V6_LI-%'^#E]S@T<OO8S449BC=
M(!WVX4L$! ZF3@"M_3C"_P0!(/K*#/=+HKXOTXE!%;Z$FU^I?2O2Q:F4XA!G
M2Z9Z/.8G>H_X+W<$ O93A@2IRXNH<>*G3Q<-0C*!44 L8D9C'G[?6H#D&#VF
MWR0BB9KW>-<1S34<J%Z9O'M"DT8=SB ,6-;N4X-&-TQ*R?"&A ?N,:1^/+1@
MX-[P?$T<R_,-_O@Q&XW%11J[&>#SDYO!HXR##SC1Z?/G,]J]>;2A>9SYJ[6E
M22-' /;FO!E*D&,T_@ZN+=7D+0O-OH"KN,02!T0!\( /6;H)2PZ&5O%>6BHV
M#F40H?8A#D@SH+>I<[V(@DS7 UHT93%:/K9W:H<(.\NTUAY0%C<GFO\JUL?U
MZ]2X5AN!);OL97Y PUTMGL-O ='AVVW.\.0UO'I,0WS-2U3?JBE>Z0^!4&1X
M!1@>D.UO"$;0_>0C:??4/'+\&0<4X0 D^H :H24-T[>*299OI)MA%)2?EVGQ
MQP?'/,LT;XM7\3G"\4A^/U%8TSUB73V0F,3;2.+,O(!Z;1&4! V\2P;4C$L7
M_";YZ=+AV>R)YT=@6!3:G@N[?>\"6?HX\$1B(J<AW?<^LI2? !;/HL#O3Q0)
M(.PX^ S@'_BPQ_C*#?W_,-(&43]+%#;PN/,EF./[$]K8F-8;N4 K5ZH'G[[9
MVMU%KAH7,&8[>7OZBL[S2 ?*8E0<:'?J-3G4"/+_?[)_<;C_?]^(KY>?SO^'
MP..3&DOW&YPE)J(PH>#!B9>#U]]>N^)L.$FPQAIH\AR?!E#C+$E?P7)_7!R]
M$8>G!_]C;82K=6<WX\W=3%+<#=Z?DY$4E[(_#*, B,I 9#9P^<>7X_]ANMC/
MK@ :1&?A>B0P4'MH\%F&<@H5!/O!R8%>AN:9:=F0TY52;R[Z?B"_Z_O<=#XT
M %T<?/Z[6HF^ VO0:#]F%B1PV#U( M@A4G^NB*E&B',0P7W7U#AE%F: C6:5
M]-WJ:>!@POQ5,@'\WPPTF[R!)G=1QK&H7"M>VS*W0_0[]@2%.^6:+Y]9866-
MIM581:U$$6S"RA:A_78Z#[$O-1@H,Z1.759!D&6!&P=\IGB?JI7Y1%&]#:1W
M12-PJ<W#S-V)TZ5!2N!87G/7-0!-WR1RY0@5,= Z,U]]F7@304;3;-8F:L[!
MALA'^0+C$J#O42M%(']K'C;SYN1S+)"-+W GPD+-:0<&!^^<52>P/,1[\02)
M&*O>(F-W<>16S.6%/KK3T[.C<X(>$TE//W\^/KGX2>1;[8:O/$(+;G@KB[?&
MX0/<\,E:^N$K"62Q&=A#8@;/<._5P8'U5:BYV,/<TUSP<<_@@.4(:7>:XDL\
M;Z%;'-0?L&4^NX#A0,^&+IR@^/SYP#@HP%R&Y;>*RT\OC2[&5%Y-[)7/9!SZ
MWXL^B-P+7K3BSR[__C]L(<->^8N-0KRAJUS_VCAO;S;P[=A )O<\4:7XG*T6
MW'[M/)+ JS=TY,(E( S:R[]EXWVSB)A_1312I&3OM@],>A(=W9&%)QH<Q.,9
M;G  "ALXDOV\XS$LF\X0!7S#\DSO-*;0 1^;,4;X.>T1'YF'(UR/S[NUVV#+
M2H4HR+^,O>/382REZ+N8;D3CB(H1&:SFIY"-_6+RHQ0@:<PAIK^AC5CP)+Y7
M#DSC/3F+(R_KI[ >>4JU@W\NPO7!XKXO91SC>,V):@JHSM<&K3L-:Y'P"0P\
M$CD:!]%$>LIQB$C!83<)]M%'L^Y$1T@^1%':PTC&9^E>91+>Z(9]L ?5=!N4
M#Z=Q(-&G=N'"(2=$"#1/1WJ^RX8LN2P\$]&HO3ZUU^<YO#X6(^CQ4#@GQR=7
M\)BNCC[Q'M"]OJEREPPB/Q]89+F)5$Q S87Y=^8G?BK%OPM'!^+HFQ\$"5\2
M\%4:T ,+J1B&M1Q->T*'3N[/46LMYM(1OP]QAA:ZK(&[%?<F_6$4N!3I).'%
M%[<28,;9XXKWS7WEW#GQ\2M!PF$PR\^C!+R@>!U&E_*OA^)+$U<H=_K4&=NW
M9VQOU<G9Q>3L3IV<_71C,^H4[26[.3[N'W^F?6 ]\/[7CY\N3T\:O_;BU[R[
MLT_H1_])[O"G]&Q:'2]KA#[0LVF59=<X_%$3C!_O,ZSSC-?/E3BON]^S X:]
M,\Q]6>R?<>^D8Y5?B[T9XWRUJ67RU->+OL_3%/O:EV3\-?R =N,4W#:6K_ 3
MYL-<R9"S8Q4LE.*9T119->D[T;E6.HG *WJ!P@A^S?/%"(B>:ST_9N\191J0
M3B:N8LR(Y3&JB3_*.&U CGKQ) IY9KSG:Q.4L&-<D#M3V"E/J)["1*D35F]?
MY?DJ']S.M,\37G@68](:6+$YQ@HPW*BWDR?-RJ+DC%+O&AMG>D X29))/K:^
MSJFBW$E,C=U@E*7\D R!.J6,;TFBI"2G4Z GY3/K-"PGGI6:I3*Q6BU.NM3?
M;I2Z<$_!H'<I=;/@PFWO[6UQ3A4LP_X<C="B][ Q;QW.N59K47HOKCEUEE/9
M:H<RSXQ'JU]>2=L["9@=^2&<B,HI<U-Q 5\X].55-&/_YWG&)F&-,:A][9B_
MB#DKR&QCHFP<C=MM*0\C7&%PZ\!J 4Z_323B47>6+#DS('GT-3<$#CM)>*UV
M:XNRI UMHH4'-P/8>*DD'Z1.5-,,F-Y@?CC0&R$3D$W)F_ 2*Q=M5E;TX@A_
M T3"6\%"G@(/UM4,J1.-01A^DZF:XDU)T_H1\K320E+TLCA,Q$N:!'(P2>4K
MI%W@X!%EDX[!8L\'G7N^VY-P^XDLH':R+P_Q.;AN!BE^#0Y+)H Z?()74#GY
M<,BQ>'D0);!3^/MK^@F63OAKGKCXYH=?*(75Y#Y=GEP4P<6\8,PZ*L,-CH"V
MSY(2GD#H>69^E NDH@:R)IB8F2=Z#]!&)H*<.? F,#-QQY1D,%XF_'YG)QV*
M?9[Z;ES5QR%.?8U,2N8?0%H,!^4F*\\VUE,$.-\5OZLR1?50'K&?8)(^,P&
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M$<)947Z8GSAGQ48"2,M-JS5)N]U0Y2#4&J7_[\S'1/+>1/S-Q3X:J9A:@!K
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M5TW<CU43=^XLGW_S1X[GW3G^HJZN>UZQ<^<!/3ZO;*?1;>W61N1:G-;>?;(
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MLE(,>D3BIZB/1SD@2AE!_R5^LQ='K@=K%@!!7$YM&Z ( 3/T!IXLFTA'!J2
M)S2J,)'R&YU+'%TC_K"9^C5!+ +0X0-$AVF;3C"0-Q4X)/4)0VKHAXOV]("F
M'O8FL"4@$S<.\"<P3K"7>Y^L<5\JGZQT1I1.F.22#:")8/]X&.RCS<814XA"
M(@_=->UZ>9!MEJ2@A(UCL(+@I,CD2*Q.[QIC_0BDKT?P^8B25,9P\-BEF=S
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M810ZY$'BGP9&Q]#?0I=?.@2>!7BL51UB,%8:637W0XX=(PPH'[,@Q151H"#
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M@BTI;K$E';8EYR"9\SK!>"50*9Y)C<>FB+-X_P(7J)Q//RPFLJC$3:K^P@6
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MR0;EO(JC*>J[4+9! N\)ZXZ\$;G.BJ953$.OU&I&@K$4[ C/B9N0@2X!MU.
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MQWZ-JFNP-V$N<%I)>A9*%H4]@C7$ #?%&(DG=O/(LQB'YI'G6A&\!57B<0C
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M2[ JU*5@D8\_%0ZBZ^B6TT;[ >/X%A^04&G#0!';C;\QXDJ/@4[8<6(6[MR
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MG* :1W,,): RGYM$S(\@&^NO7P 3*ND"1:>0L"RF)&!\B&RI"%/,4NK/(M3
M*<8F DP4*<.R#*8/"_$'>OAASV[V]+.=KK6G/M(?;U%C<>SO[\AEV)[]I.K1
MR?&ZGOFMBYVA:/!]#C KZK."VNG^2>%K^3DZW9\0#DCP;R9UMC>ITH:C?[K]
M&S 0$C>-HB_BF*09Q<O6XM_+)N.='BT;-Y\Z6*ED,=3>%Z!6J9T^.B2GVNH
M=+X^Y-)T4;[EZ3>(B3^":ND,6<A$S +#+&?EK:O>JR9W4/!VQ&@(SCWU\1J#
M-Z!N&#)_R\>+9F#S*-Y_QYB][J!HUZ5C:WC*^DUL_FJFW^!^ E!+ P04
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M0T-C1V=7=P_E8^^G;X/?AX9'1L>HT_29V9]S\[\6%EF_5]?6V1N<S:U_<8D
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MC6HV?_$=>B<,6(<RAB86\RK>1J#F<&7JUIKBHIOX6.A^$=-; V>\D,I:R!4
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MI\@*O ,?FC6[(O#B*S0'%OG16DW[9.Q#^&T%E_V_3Z(IF1[)-O3EC)KJ"/?
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MBH8HY:'B04X40DUH8ZU&6D']@_4?4N:C_6_N?>U]G[(SRZ;_U:0=;OV;@^.
M]L)0T_+/"&P]O#OX0)>OVM7W]Z_=>&Z=Z&VNE/LB]_5BQ][2S:79G*%#];95
M;"]A06YWY/_E2R95?U^GR6&")^<)3%U9S%FW;VOEUP1 O]OEX-Y^N-:M=.S-
MUM]@21<Y$3(&WVF< "E)M4%^G4C_$Q7A.<)64J*7NNT3JVK_-IOQSEWS_F)^
M&=_-%;'F+-QC_8K(]DFU[[7<SYXD%U*4^5]M^90Y>R3C:_X\:5:5LV.0K<>O
M:3X(QG5N(*MP??AZ^=:Z H*D:KU)2+SYX2+UBK_75/ZXHNQBKR<2]/=FU>S]
MJ^_'O Y^7LQGI.91W2<NN8\M5^;71XQ7K3L;IS_14_JI]&Y2?S6WZ.S5PA]7
MO8\YEBD9%[_(:WA3P3TT25FN3",&1/%3%;<\F:T%)3_2UVR;G!IDN"7UI_+/
M:?^X2:J/;;\-N[S/"PERVZ,0G7V*"# ]@=FE8IZU@?MV%P&PUC59,RU1D:^8
M6P)@O3RA1;),*S^S9<2+>K_BP1;LO4^ZXG%]GZ2-6TMT4G7 66QEUD=LD;\H
M$<% ?8GD*?[E32& MNE<,_). 6 F)@#<H>0Y >"(B]M$SELS^[DR ?#ZX#KN
M270C(:V2)P?W0Z5&A72G6/CY\%^'#Z?5_FEBN;MS!V0O.:'$_"6E[T-#=M[,
MU[WBY,C-]LH*PB4^[W*]?Q,LER0^Z*XG?K/9^+U)I?RZB:>0IT)7NO$&-/"B
MCDD/BG-DGB</;6%TR+7PZ<@46-T)O7MD9@5>-#_FJ=3")G+MD4^V4L.VR1]1
ML9NP1>W5<;85/UX?/O: '<LOAXS',...K!-%W*N856A?$.IBTS=X#?Z]AT3,
M'1G'<UJB7T(]C7?9*>Y^U#>T-/\@N.YNTQBC.#NRQGAU5Y-\<K>/(M+AT@9R
MX()6/K^.\3-LU0.2EJY]>$0 3.4I/FV'GOMQT1R)I2QOZ!J"_27&AF=W;BN<
M^!P?8B;!?I0"[22"N(UI5#I6'ASO@H2$76/*3,L(U:2P$P9@_!>3)_=[XJV^
M?A<E[&G8GB!RO.+9,!E##L&/6MKP/U3 _7X9(%0F,-J0'+)'1YL^5#*ZE%#$
M;[QW*GTI0NPAT":AO)]5_P[Z@0<1*X_P]1L/3>&O.9,S[F#6$^QV3#@AGJ!@
MJGF?GS>3+A+8LEZQ3PE(G1<3_4IO22TR[K@!;OJ(+W_7OD!277"8\&SM<RM>
MMQMW@YW- >=.[TOY9].YJ.]*^8/RB8"F(PM^W\;OP4_A3'&?R* +(8DFR8L&
MN70:TX%K+)/HI0\.5Q1BR%QDQTKQ@O>EX72K.TU7M]TQVB-U.!A-E^$<U5T:
MHJ-B! !HG3Z:PD9S8F?492B_.2AV&@<_U414P#R +$B0\DA=OVR:(E?FR:3J
M\*#&9J^Z]MJ.54AR@GN>9U<W",&@ ;)PC$HC*^ DJ +@HW>[0KUW9U0^^8VT
M55H%(R9#H@IF#_1%D[G7\>UGFD6X5Z!^LCC<STRFVSV],UV"MY<U'\-SF"[/
M.0OG7!S7$(.SM 8:;N1BFUGI=B^<5W,-Y7]2NTEGSIY7RYQKK*W+.AW9]#QP
M*P(Y5][YLAG!3G; +3[TJ+NWP%#5>I&Q$#W>6F].''AG>I1K GU1^,:)/$^J
M Q/;^Q]9NP[PS%ZOJ2!CL7)+^C?#'DJ>%U&>5Q9]@]L&45P() )/7K5=)9$9
M0)<9E[C*$05GNB MEF$:.#.=U;E;+1!^X]N:68B_">/B)^56>W,N7+OI80.4
M>6M ?PVL H??EY?Z;[@[<8+9_[@)  J4<RB#JOUKUB]OZ5I^P\'$\U=PNP/(
MH%5Z,D&$9SUSGWQ+=SR';KW$ HMZW'O**KRP>BK&K$.O_E[,GE(VT;AH O3V
MG#.=RD42$KIOW%H]G/+BS3_9S^WLOB 'G7U'3K1D?EFD6>3^?%5RR%E-Q<ZT
M[)*9^M^9]9[AM'(N=(RS#V300SI@'-WY=N'G/#@<6JUNL@[>5P:FQRE;RK(;
MNJ=N(-3!<@-U=2X^6D^5K989N1K: _"I1*%QF) ^0DW@P-..#BWQP-I_%^H-
ME!PJ8!L#1HV$%"'JB "8E<KO?!@Q!4IH'L/-\W/Q4T_,)?CY<'3(=MR(>T@/
M'H81YH :$M/L-!VBX<D[#Z=F$]*;KQ K9=)4/8Z=M'.5;Q>[/G\X$#+"M1/>
M^R7BT;1T&.BPLC< OH<7"J)FK#MAU)%NS6E*#WS;)-YW,5MDQ"  YCE@=:=U
M/[@J)VFD5^:K''S.G(?^B7EWR)]<IU ;T&V@@3Q:Z:.5,1:8;?MG_DK83)7Q
M-=KQGI_7&JP-YL8O,3UJ(M">P31/C7JX/WZJ63A]^@A%2[L^#KZ ER77M-*(
M_E3?E"FS0TNQI33.&B. _^B> ^'5A[.NN[9_G-&$)PH 4DD\9!P DQ+VFH3(
M[&52"<8:DF5J=PP;X718W2^_-Y^:1B1+G =7_1$SUZ4C!$"'R:6PN!;8Z C#
M^B%Y*BF*G-:JR_&@&S&KN"[")+%K!WE240:$;3PSEOK?@Z:[&C//!(58VK<W
MA3YK[]T_!1L*H2:R;3FGN6X\N>%629XGN,(FQ!DXB_?0>^$UX7"9Q3(!L-\3
M_>?U[EI#L'7EZ79[^9/(T(/-J>33[;.$L9<>#;1L9C&D-;S,]=H(YBLOS9F>
MR?'[K-?]^]VS-ZH7#(@Z>1GN#WK= H@&(UD_:_\=;*=JJ)E)T<+QFVG+/7OM
M5U1FQN=[E'8\ZX1*V(&)NN197SV+Z^>TVV^:0#>@ 7P5(9WL+0 X?T@P45/,
M,'K((YR.*Z9HAIQ@?MB?2NJD;2K4RE9RQCMGO-J7X=.:HG?4YH.CDOFRB9#D
M O>J&R<2DG=.Y\DQ9H)(;2N<WS5@"=LD?:\P=;H"X!R*V3>FQO4SV$).$4<U
MV=$@<BFE%-<]8_O=@!A'G4]8#Y)Q0^P)I#@.&1P>L3 9KOW]-+12:'N^_?&%
M3[VQ+0FS03]SID]^^:SGM?XG4^G@K=GUX.&[USY[U=>3!E_=F3/:%T=BHYMO
M?GN>$UGM7A'<D!U,Q2)7<75<;0SYTC#>%Q;KI3D0?D5OWJJ)8S%EVSW4.BK^
MTN)K47]?+M@6-TBR%X&G_-M$0^3]O0SXK>2IRDDMD,FOK"M<1*EB]88CZ\E'
M6D1=6'N.VX6V&?>?DPY+CGR(GTJD*9JK+FS0=O#4A1)*@C,Q31XK7$7.3[]X
M4R@\AP['L^/X286,G-BO9N;V/V9SI='+*Z,[(:DL4 ! 4OR9D'1(D^-'ST,X
M@AL]9GZ=BL,XM:';0F8Z#>K_B0$-EJ5;GG;="M)LV/:^U3FA8^[N$[^^H\;&
MY0;L(FW#Y^CR"%)O?M]QPZ"4+O#3?;]CO=[&O31KS*6\GQ6$*ROX;IYP]\5<
MFN,@%2ZT4T2&P'Z00A@7==9D\&OHTJ^6K:P=VDV'A0.WVKYY8;))_(0H/T@U
M<:H'#T86S+"^1#,^</J$'OQ9&D3N1:P]OX#L&T*ET1%+_:$LZI(7[X801OSQ
MGJ)B!I4 -TP9L K-N"-Q[5YW]'VNAY"2IK?Q@2OQ^!ID)T(>>W5D;5,XS(<D
M>6WCY)M>9:>4!7H9#9F*)Q>$%SP]7Z7Z>R?V2UALVRGE)_)SS_HJJ9>.3DQX
M9(P;#K.C#D%6KM@:9?XKTY)]JD9G/OPN1Q][<NGHZR8!<)G7,1@>(HTY"TGK
ML7AD)5Q_L8PZ[M.D?#4_?]T3+WK9I/ 9OS%;85GB,4R%GO_2\8[E77@A82\:
MD@$G8TL9^;I#^E<4.]G#,6C%*+YP-/4]LGY&TWC>#&&\XPZ:#A\G05(4$,]>
M 8=CL"A\A7#Z\>LL[R%S/%GX=F10,:>H8^^IWB.S,][J8YX?>G^\ XZB" 3P
M)RH5OZ^R=O=.=JE0N,=BO3E")Q;-W"!:)\/VU'0542@;@QBY!*):N(1<>7.)
M7@>^SC=8VN2(&^W'L%J%A^W=Y1?L0"XCH=-OTU?GA@M2N7ML53^GQB6J:6PE
M.F0N.DU8;N+\1Y J](.*ZM!FPNEY_1T(X;^[0M*3(3'>>3"S*N]2^V/5'#4!
M$,()K\J0NVOCG4&!YVZE,\\*C36$<=W$_LDY,$T;EW &$4P85Q_KP'E6C-6J
MYB1-3_-?S51(.(]4-^Y#QR9643Y94,*) WCJ/"25-!5"M>J?-JP0RI21;MVQ
M%3J\#2^I^Q"2QS1-TY+"@QHUGA<&"8 DJ[K"$ &0' \$6QQX['C5W D?@Y&!
M)#=F\O#TD1AS3=P8O&X^70 $ZL"F#R?I$Y1YQISH\@7M8LS-SFX5V9Z4=XQX
M6Z/'ZN)WWR!UXC\J^[C>QDFW[K[.<LMV>)B1>O7$2D6#NU"M!'AXM 05/+F1
M.:-AX'WGE4OSUV;B,*MEI84PU8*XS:_VIG&Q^':S@I2GC;3N@SW&QQIE$LD$
M..'KB#,W%->M0J)$(]LA,XX;79=SSES3_4>Z.*:IRS#2S\YDI8-_YQG1/]5:
MF1MO/0DW#TL=&2 KX7T]0I+A&F0_X0SW&TTR":*T]5EV4>.+,W3T#/J9'P_$
M!9@R#]R0R W_.)N]E0MM;)C9 >K147[Y_!9K\UJ$T1.5!%?ZN$/),6S3PJ$)
MZMI($,UR[OT/";7/\MVNV+&[[U:2- VTW4I[\LY@;;QZNTO*4^J'X:?AM^$)
M&HJ<TT)*CG.ZP9$.!?N 5A@8V<ZN>N^41@HLL)@O.V'%FP7/J1WQIJ,T6E4Q
M&_22I5-<3?]\ /P!:7VOI<GR1(?K'J M5UT7W*431-&BK?MF;X;&W)+X1D:0
M_8EQAG!8JQ36@@,/?7OMUU/,JE60 L.YIK:WVA&I=>+<_$Y:;.S('ZW 5_AU
M%%6U@WHH;3I(ACW"B2O^I;+[25:1/]NP577 <K>NI3+U/E7IKLP_5F&KWMG-
MXMJ[CY]N;D"=_L;M+JYHK&[.(8>7S88BI&;\YPW;?NJ:]!9TGBSQ;[WZQNY.
M@-M=1I1M]/)X$_SJ!6;+FXKF5=D0MJWY*&.D=!&/FD<]0<DUV_APG?'MYW$B
MF,-MCN,,G"(_"U^/^P-[<62M>'>)*X;@.3#^Y]=[E]=ZKVF\/FK<VX/^MDR>
MRB<H-5_97\U)Y_KQ?(9-S:T8?9J7:SQ/$:O-[</K?/=S=^6"H30F+096 ^O
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MY>$11JX&1%Y$V%*N\T6(6$E;<QI9S$X'= PW6U#X-S7 +3I&_,;R$0LM!VT
M,@D^$4F'*.+88;XK4U"@C/@ED3Q,GO<PL4T]%2AK&":4V[;%4&(>O[&?F\HZ
M4R@4H-I-3'GLNQ]E$['WTDYVUEFOV;!#5 3Q#'R\[O94P3>V(B^7;^QWT\S!
MU69BZG)ZN"1B TH6DD16-TQ]RUS:X".%Q(1QBSA(4R<(? ) G@F+D(!;7!SB
M\FIQO1R&F(R"\GI)+,K"%I-FW*,14*4N2C(EC6$_]&2+U-J$HE%)D]77D_+^
M]"P[+7@F)A9U:."AXWV$(0U"1#D61=\Y!LK!&_1^LG(;BIC(ZVXI:[#\I]()
M*?KKZ8B83+RWJEFOLOIC;7+1Z*_G)6)B@@]DM5*Y[P_7WW(_OC\Z810_D5S!
M7>9GXZ<%&=2B>3-/"_FK['307S O/W.6AM?AD/=09YDWG^.,T^7&L-'(]J[@
M++ZL/ADSMT=MIWOV,LIU9[5A#855^\9[R+9:+N^'YQ/8N?Q:N?*]0F982-WU
MLN/IR T6@WM\>S>F<:/>>W 1O$M5V 0^==RF9S=S=_<FJ5\_YH+<U3Q^OIZF
MT&,K[D2D;@ZME^[42$5FO+Q].*N31HY,S>?/?=/LTPR^Z=9Y_ZJ3+Q@+.S4T
MI_/A\ZP+!\%RV,XYP<+]:N2M?NO%OKN,AJE%4+%RT8,1G>>[#31,M<BW2[(T
MXIG=;+4RHUDM_P-4>_?)>-@]#++&?=%^(!\&]^U?*:+J22UP(CDD*L2M$X[Y
MHDWDF%)G3P-8R.I1BXW$[!+9]KEL&(88=HF+W4?A#JS\@1V'%_"UAS?>(X;<
M6U)6SZ_?E#5\;7(4NG\87P/?)K6+=2S/B;SWHB9-@7M=V:HNW)-=I<_PC4 G
MLBU>Y(!R0 X.W7=T'ZSF?S=PE+LC$/E/3W"Z7-(S63%JTC%SE=Q\G,56&#[&
M(L']#HOW1O<A!BR9R+N@L66%"@.1Q]G&C9++WZO%P?G]'I]?(=5_MB%RPNDX
M?.<XL2,)0+8BMXUZ<A=>WQM/:X- [;1@XV._!Z>FSI"3'@<SR+!S"HG7YO)A
M+_ ZZ/I&K:(>5\:*S3BU'%'TU416E[:B6!.?#6V.?"D)&K#65F(ZTTC.4F4E
M9BP.W+["N1%=:S'!GKCGR"F[LF61 &,>R=TF#:(P"8*%^Y5TRY'_\R26:@C#
MS:>#:O?_4$L#!!0    (  2(G5AJ!O-/M@<  &9#   5    ='AM9"TR,#(S
M,3(S,5]D968N>&ULU9Q;<^(X%L??YU-XV9?=2A%S"4-()3-%$TB3D,[%I--A
M:FI+V *<R!(MRUSRZ5>R+8+!=@>L3,5/31OYKZ/?D8YUCD5._UPX2)M!ZMH$
MGQ7*AZ6"!K%)+!N/SPH/1K%IM+K=PI]_:-IOI_\J%K4+B"$%#%K:<*FUB#,U
M3%OK4X#=$:&.]A_F_%<K:A/&IB>Z/I_/#TW>QC5M"EWB41.ZXH)6+')!*=FB
M4 B>:-<$:\TIU2H-K7Q\4CT^*1]I#_V65BE5CH);?CM%-GX9 A=JW&[LGA76
M>EH,*3HD=*Q72J6J+AL6@I8G"W$ATGY>]5N7&XV&[G^[:NK:<0VY;%G_<=TS
MS ET0-'&+@/8%!VX]HGK7^P1$S"?Y"_MTA);B/\59;.BN%0L5XK5\N'"M58F
M\C866W6S+E#3@R\+@I>FG5*"X#T<:?X03]AR"L\*KNU,D;#<OS:A<'168 O'
MXKU5JN5*T->_SXGI.1"S)K;:F-ELV<7"R?X("YK0?;CO1H;*)GQR3*'';--U
M+.%J73334Y7TT%! S??:FL!.#EU J_E#L&S>K9C;10N.@(=800N[63=]I6%C
MIO-;]+"-OGT[-_8?L)4XP,9[FQK<K0=+[(.,G7 ):GI#6%QUO)N]<0*!R1\'
MV =3=* SA'1'NI%;?3L_RDJ T&ZVB1M6%O%Y:F-;K*L>[SMB%5PPB"UH2;O$
MS=E7;]@Q[QH1,](?$L&04-D= D.(S@H6M/\G!==TN+6PRZ#C;E-SY>!=:!Z.
MR4SG$KH(5.*#'[$"[_Y*6%=D:A\,XYR;S<Q ]&T!1%S9I%%SN>=E_^$D>-\L
M">\94>*\WQ&,_(H$H1:D9P6^=0CF\HE),..SK8V@N(&O!S@6']Z^1\2%%G_D
M4 ^^Q:F=_!),Q'LXMEW&=Q_L&W"R^216,'PT*7?&1B3*XI9X$*%+RBG(=R7.
M-WEB5V@LG2%!F5!'E=:,^;20-\8>TJTDTMTWRO1Y.R61Q1=:&?)IN4;''6*M
MIL6)G=&V/$IY#QW;-0%Z@H"VL77.\XU,F!-%/S" *\2>S"1TP5&R"_8+U#Q3
M= @V&#%?C G@R>"-QT3Z)%:5@K"=*I\/G[R'4^B=FFKOW'I#9)L=1 !3X(QU
MM<\?@F((A)A_5QJ'FMP@2QC502#;E(\JY>'QN3'VD&]=V>-SI7\.79/:TZ!
MH0+QNF .-H/Q($+>QPHW@V&TXCU1@+H\JUQ<P:6*0+ZAN)X<?%KJ"3!"[ WU
M:4_X_+Z'4T*9V)<RP+QLF7.J<!YB3#H9F0^55#\ZOQ/D80;HLF,C2%7X8%,Q
M1TM@"X;$GI:'[DO>[Z/%=ZUC0E6$GJA>GC:-&R0D].3T=%_DCQ"A*TSFV(#
M)1A:7=?UWL:0 7Z2<I[<D$A'.B0ML=VW8G +J4TL%3EMO&(NHD\"#,D])9O-
M0/XM>^[P*VKJUIN:>7CP)O*0^!6FJ]&^ G>KIK^NFH,M?PH2Z8#41':_)X'A
M (2^>"ZWRE6QZ8GJR97I'P_XZ_'Z>^WOOWZ84V_QA&L-Z[4^&S\M\<.Y-[^H
MTT;]JO+\T%^ZJ#XS7TOHDNG,@)>O]>K+HFSV6&G0Z52,*WVV^-)Z*LTL@P[-
MWM'/4:TW.Q^<PVEK^ T]5KY^M5A_>CS1+[_<-J\<U"@/&@=W1F7\/++(\N'>
MOKD;TT6G;3Q:4+\[:+H3_>G2ND##B]K=?16WKW_42.UJOGBY?CZ /[XN+CW<
MK@[ S]YSZ<"K+EYO'H_:N%/#S]67W_O5:I^6[6^]-NM?7=8;I>7P8%!]G@]>
M9CW]@;P.NC63+*W;4AWTO_X<WGWQ!@=+T@0U[['D'==[G9^#:>O<[0R_WQZ5
MS!E[[ $X@7]K+>->GJOXW%,V=@K)R9I<%=AWKK8=2,<\%[B@9,XFXLP*P"HV
MC/&Z>:EX)5"1;D@N%NP9,"9\=Z2.?40N#T_). J2=4J%8%?877-$FYYE\V^;
MC$&7^59E+CFFR.9B@YB&1;[,2RD-9-@E-C'V  KJ$4HV*1'!'.U/HB D]-3"
MP-YO4<5Q1)^%0NY;HOE(39.92!>H+Q.(>L0W;]WVC&694"P7H68;@02M]KVV
M/(EE$LK]Z=LDBIVP13S,Z+)%+!7G8=+U<Q!^WH5)>BBU4+"?@_I@T;6XK?;(
M#HX&*UL82<KYB$N_H",]DE([V-,A3<NB/.$(_Q'VE14X(TXU-ZLC%HGTP <4
M#[;[JWR("RIY=D'ES05I*7$V%[3XQQO:)_-LK\N3-/.3F,7PD/137IMG8N\_
MAF[H+24S._@9B2('; KGS@M;9*0K%";*D0YO"<\(T<">*MHUQ<KF:/<:CT4>
MSU2;*(LEUZ009$8?$?K\5;CHN"7;Y'QX5Z[BIVCH=D*PBE1L2RP7DWD;@<2<
MEO/N/H4-:'J4N[-<&?9MEO&W(5MBN4"]C4"B5IOURG[:"W,"\!AF_ME'K& .
MMHWQ("3T#TADNYA!"DQFS^ Y8" \:*6DQ! KG)]=2Q(9Z8P/>?^-#>:P-J6$
MM@COSU12YG^'?#ZJ"^_A)-V3EN#N?! Y>,>0.2JMZ^0B_D<&+LFFYJW[LI4_
ML5?!=Z65@X"_-7Q).>U8][Z0.S9UNI8*Q*%2'J+YQM@EW_2D\U2/_N):GEQ9
M_9T'T>S_4$L#!!0    (  2(G5@5I-$BRPL  *Z*   5    ='AM9"TR,#(S
M,3(S,5]L86(N>&ULW5U;=]JX%GZ?7Z'#>9E9*>76G)2LMK,H@82$7!K(I$U7
MURQC*\&)L:AL$NBO/Y:-*;(E&6Q7PGT*@:VMO?5]EK9NV^_^GD\L\ RQ8R+[
M?:GVNEH"T-:18=H/[TLW@W)KT.[U2G]_ ."/=_\IE\$QM"'67&B T0*TT60Z
MT$TPQ)KMW",\ 7^ZD[] &8Q==WI8J;R\O+S6/1E'-S%TT SKT"%?@'+94QBJ
M;&-(%!Z"<V2#UA2#>A/4WAXVWA[6WH";81O4J_4W09$_WEFF_332' @\NVWG
M?6FMIOD(6Z\1?JC4J]5&)10L!9*'<_(%)?_2\*5KS6:SXO^Z$G5,EJ"GME;Y
M?-X?Z&,XT<JF[;B:K9,*'//0\;_L(UUS_99,M MP)<A_Y5"L3+XJU^KE1NWU
MW#%*0;L!\,[21M#J>U+ M_W074SA^Q*<N] VH%%:?HN1!07&D)]]BU9ZB6:D
M4SHMXA3"H4J_XO<E YK_'B%]-H&V._3DPI_'&-X'-3I>E7YU#M1?/Z#GBE?$
MJ[;>(!_*Y /QZ+\Q194/H2&D)LJ4D$7;N.=ZY(9]HBK!@W^MD>53P!,@[(=V
M^690^A"* "+SKN(7IBQL8;J]-*R'-7D?$TQ<2E1TY%%IZI:M=4/O,9KP6]I%
M'!\J'S)@V;+MF69=PRG";BZ84@J):=+!7;<@">1 %@3"*[2!*KQ9:$1QC[E7
M2?4PMV<8>]JZIJ-KUA>HX8YM''D=<R82<)4&-LKC L\0#A^6XB"0!Z0 \$H
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M][U2R_'$^\;[9Z0YD$C\'U!+ P04    "  $B)U8YIX"'W('  !T1P  %0
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MYRBW2J[6\P@V3/*6K^S*O^\2HM:L$YP%[%?=&;F.T9N'S8SSJ'/A@/* N3M
M8Y7^N\H"92_"B,-H5XJJZSNX1(\2!RT"7$]TH+^$PV"C4&?'6@TGPS:PR6.@
M+Q<&6G(.QBW4D8&I7MX<VL[K&.UCY*XW8@AZ"R+"%L#1^JM^5K;1G_<,LA7]
MF.&\T)>UQU%DZ"T8V,Q'2"X--]M 3Q6,%ZC?PN:%:<*M3K<BMKC MFL:?!]@
M#*QV9.#2X,+("-WJ0=@R,=#>SX;N]2PYT*=N#SF9H"25MC.+U\4QU_N9H9Z-
MPZ8K;8>V$[*RAD*O^])O3"#9\QB EA7 NO[7?<PZU+0]TW >@8$;T#JF66PF
M%DM%$\OH;\QFN2LQIU+V!6NSO80^J;@(Z@29S_J0]M>[\@E+W]ED%K"SK)27
MA=Y[G(HY[FV+X[7?<VRSZ2"#", VJR;#VI?B00RD_-$+8(W&;+&XFXZ1;08E
ME>1( ^9Z'T/X].%IP&L<Q\ SL3V*'N%%P)@5E")13K<B)E/90J(<+Z<T(FPX
M+6B!X!Q,1>PU<XJ_U_/B6[O+O!TQH'T!@#8E%"4MMV"$,&&Y/;7/SU:N6"DL
MQPJWVIN86O7#%[PHK&_(\:EM>-JT':HG@-6\HE23:L$._EB:N3ZP&9XPC#K-
M^P<(BUCQDGIRI=-S7G RV2L&F\Z=>^ XYQ!-H X,#T%@M3S/!U@ IF7*<@%;
MZ@]'E[G6D*&P?@VPC2P1M89T14F6O25V<$*9JPR;XOE5^&C2*V+>\IC7E"-]
M6.H(9[2%"D(RIFCLB.8TJRK%8],*4SBJS+6%S3<KW34<YZOOT>@]$6E>4D^N
MC6G."TXG>]&!G\/X?G_QK?SC^X,Y\H-'6*Y:+Y7QX'$*[X[]R4D%5ROGVM-=
M9^HYE;'Y4G#.B$IT</92*3T'1;--"MUF4]//U7'PM?Y8&%LZ[IGMO9_]<GM\
MW#T&HWKOTKG73D\MTAGM#]6SK]>U<]>I%KO5G1M=&SSU+32]N[6O;@8X:#;T
M>PNH-SLU;Z@^GEDG3N^D?'-;@HV+AS(JGT^"YXNG'?!P&ISYL%'J&C_;3X4=
MOQ2\7-WO-6"S#)]*SY\ZI5('%^W+=H-TSL\JU<*TM],M/4VZS^.V>H=>NJVR
MB:;6=:%B=$Y_]FZ^^MV=*:H99?^^X.]7VHU"OS0E9;_U\CAZ_C8N=:IE:\__
MH=3U6WZ 9:-1W7 !'M"GJ1.,)F3(#M$84$2>G*XK3V%SB2]\I&<OXFRX" UI
M2BB.4D).CMT\S0=.14#E9ETL+;./:[YET[_6" %>Y%GF0O0*64GRXE7&<%Z9
M:S:;IETU"'W#B4I)0C*NA*!4R5;2"OX>MHC3')L?)&!'.&T6O4!""Z*R9%S+
M7>&PME? 816E2]_M":G9S(A)LL8MFL"1?/@AD$9\[L]$F Z.,&Q6( =UY$."
MIW5DB3BUMEI?BG7O749QC +.B&PZM3I&T+)HG^R^'9WC%C;/EBG+LB"^X0]G
M)Z"JLR&ZFF51][SX!^M'40"V-%6)9ERJ*9S5%LLZBW%I_PLL36Y8VB]8(JH\
MV6#5Z<LKW$&3; =,EFG*]""<X@CG)."@229*X;9ZA:\Q&MO19Y,$H9H7EI#7
M@C<<VA9*&(G KA%]4G>Z]DA0QI@J*U5ZGVX,Y_7A)0PVTVL8&)GY)(1D*,PF
M>\Y/<6>O5*Q+@'VPTKD>(BCBT7=!3)*YL6@"!Y*Y&K$N#QV8/J9CHZCU.C;)
M^#'$!3%)>"R:P'E\>"F"A]((S*$!!R#S)^92!:7(IM.MX&2V6%UH0:IDF,0>
M@V.#&/'92B$5HE1AF5*T9=YP;%L]+@)UXI(&Q@C7$;V]*>3=IG?(RU(<>H]3
M'*2(JL/:GY*(WA++O";.ZDBR126ZSAED+B9L"(!_.X8("*]:4NQ)"P9P%"(^
MF+(ICJ:-W98E D:L),>&,]=[3D),$>!0G?^ZD_!;:UZ_]87]]A]02P$"% ,4
M    "  $B)U8,8T+M2&8  "?R 4 '               @ $     96$P,C T
M.#(Y+3$P:V$Q7W1H97)A<&5U+FAT;5!+ 0(4 Q0    (  2(G5B]N2LN'P,
M ,@-   >              "  5N8  !E83 R,#0X,CDP,65X,S$M,5]T:&5R
M87!E=2YH=&U02P$"% ,4    "  $B)U8P%]GZB,#  #(#0  '@
M    @ &VFP  96$P,C T.#(Y,#%E>#,Q+3)?=&AE<F%P974N:'1M4$L! A0#
M%     @ !(B=6&K2='SQ'0  +1\   T              ( !%9\  &EM86=E
M7S P,2YJ<&=02P$"% ,4    "  $B)U8I=+03%P$  #Z#   $0
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8;6Q02P4&      @ "  E @  2-T

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>ea0204829-10ka1_therapeu_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="txmd-20231231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2024-04-19</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-5521">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-5522">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-5523">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-5524">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-5525">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-5526">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-5527">001-00100</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-5528">THERAPEUTICSMD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-142">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-148">87-0233535</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-5529">951 Yamato Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-5530">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-5531">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-5532">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-181">33431</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-5533">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-5534">961-1900</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-232">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-238">TXMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-5535">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-5536">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-5537">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-5538">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-5539">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-5540">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-305">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-311">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-5541">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-5542">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-5543">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" id="ixv-5544" unitRef="usd">34439072</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-5545"
      unitRef="shares">11532443</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="c0" id="ixv-392">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-397">Miami, Florida</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c0" id="ixv-402">248</dei:AuditorFirmId>
    <dei:AmendmentDescription contextRef="c0" id="ixv-437">This
Amendment No. 1 on Form 10-K/A, or the Form 10-K/A, is being filed by TherapeuticsMD, Inc., or the Company, in order to disclose information
required by Items 10, 11, 12, 13 and 14 of Part III of Form 10-K, which information was omitted from the Company&#x2019;s Form 10-K for
the fiscal year ended December 31, 2023 (the &#x201c;Original Form 10-K&#x201d;), in reliance on Instruction G to Form 10-K. The Original
Form 10-K was filed with the Securities and Exchange Commission, or SEC, on March 29, 2024. The
Company does not expect to file its definitive proxy statement for its upcoming annual stockholders&#x2019; meeting within 120 days of
the end of its most recent fiscal year (as required under Instruction G to Form 10-K). Therefore, the Company is filing this Form 10-K/A
in order to include information that would have been contained in the definitive proxy statement into the Original Form 10-K. The Company
is also filing as exhibits to this Form 10-K/A new certifications with respect to this filing by its principal executive officer and
principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002; accordingly, Item 15 of Part IV has also been
amended to reflect the filing of these new exhibits. Because no financial statements are being filed in this Form 10-K/A, and this Form
10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications
have been omitted. The Company is also not filing new certifications required under Section 906 of the Sarbanes-Oxley Act of 2002, since
no financial statements are being filed with this Form 10-K/A. Finally, the Company is filing this Form 10-K/A to delete the reference
on the cover of the Original Form 10-K to the incorporation by reference of portions of its definitive proxy statement into Part III
of the Original Form 10-K.&#160;This
Form 10-K/A is limited in scope to the items identified above and should be read in conjunction with the Original Form 10-K and the Company&#x2019;s
other filings with the SEC. This Form 10-K/A does not reflect events occurring after the filing of the Original Form 10-K or modify or
update those disclosures affected by subsequent events. Consequently, all other information is unchanged and reflects the disclosures
made at the time of the filing of the Original Form 10-K.&#160;</dei:AmendmentDescription>
    <dei:AmendmentFlag contextRef="c0" id="ixv-5548">true</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-5549">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-5550">0000025743</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
